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SUMMARY 
 II 
Epidemiological studies associated the intake of vitamin E-rich foods, but not of vitamin E 
supplements, with significant risk reductions for neurodegenerative disorders, including 
Alzheimer’s disease (AD), and other lifestyle related diseases. The underlying mechanisms 
were suggested to include the reduction of oxidative stress as well as the modulation of the 
expression of disease-relevant genes by the antioxidant. Rapeseed oil is a particularly rich 
source of natural vitamin E (VE) and considered to be of great nutritional value because of its 
high content of monounsaturated fatty acids and the polyunsaturated ω-3 fatty acid 
α-linolenic acid. 
The present thesis aimed at studying the effects of graded dietary concentrations of VE from 
the natural source rapeseed oil on the occurrence of oxidative stress and on gene regulation in 
brain and liver of Fisher 344 rats during growth and maturation. To this end, three groups of 
8 male rats each were fed diets with deficient (<1 mg α-tocopherol equivalents (αTE)/kg 
diet), marginal (9 mg αTE/kg diet) or sufficient (18 mg αTE/kg diet) concentrations of VE 
for 6 months; a fourth group was fed the VE sufficient diet fortified with natural αT (total 
VE, 146 mg αTE/kg diet). 
Feeding of the experimental diets dose-dependently altered αT concentrations in liver, cortex, 
and plasma. The responsiveness of the tissues for αT-depletion or -enrichment differed 
significantly. Dietary VE deficiency for 6 months almost completely depleted αT in the liver, 
but not in the brain. In agreement, no changes in the oxidative stress markers F2-isoprostanes 
and heme oxygenase-1 (HO-1) mRNA, and in activities of antioxidative enzymes and 
concentrations of glutathione were observed in the brains of VE-depleted rats. Furthermore, 
no differences in the expression of AD-relevant genes were observed between groups. In the 
liver of VE-depleted rats, compared to rats fed VE-sufficient diets, HO-1 mRNA and protein 
concentrations were significantly increased and selected VE-regulated genes were 
differentially expressed. 
Recently, micro RNA (miRNA) were discovered as novel posttranscriptional gene-regulators. 
Dietary VE-depletion for 6 months reduced the relative concentrations of miRNA 122a, 
important in lipid metabolism, and miRNA 125b, important in inflammation and 
carcinogenesis, in the liver compared to sufficiently fed rats. To the best of our knowledge, 
this is the first report of a role of dietary VE in regulating hepatic miRNA in vivo.  
In summary, feeding of graded dietary VE for 6 months affected mRNA levels in brain and 
liver of rats tissue-specifically. Furthermore, VE deficiency resulted in significantly altered 
hepatic miRNA concentrations. Thus, the gene regulatory activity of vitamin E seems to be 
mediated by both changes in the mRNA and also miRNA levels. 
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Epidemiologische Studien weisen darauf hin, dass der Verzehr Vitamin E- reicher 
Lebensmittel, jedoch nicht die Aufnahme von Vitamin E Supplementen, möglicherweise mit 
einem signifikant erniedrigten Risiko für die Entstehung neurodegenerativer Erkrankungen, 
wie z.B. Morbus Alzheimer, und Zivilisationskrankheiten, wie Atherosklerose, koronare 
Herzerkrankung und Krebs, assoziiert ist. Die zugrunde liegenden Wirkmechanismen 
potentiell neuroprotektiver Effekte scheinen sowohl die Verminderung von oxidativem Stress 
als auch die Modulation der Expression erkrankungsrelevanter Gene durch das Antioxidans 
Vitamin E zu implizieren. Rapsöl ist eine gute Quelle für Vitamin E und gilt, auch durch 
seinen hohen Gehalt an einfach ungesättigten Fettsäuren und der mehrfach ungesättigten ω-3 
Fettsäure α-Linolensäure, als qualitativ hochwertiges Öl für die Ernährung des Menschen. 
Ziel der vorliegenden Arbeit war es, den Einfluss steigender Konzentrationen an Vitamin E 
aus der natürlichen Quelle Rapsöl auf Parameter des oxidativen Stresses und auf die 
Genregulation in Gehirn und Leber in wachsenden Fisher 344 Ratten zu untersuchen. Zu 
diesem Zweck wurden drei Gruppen von jeweils 8 männlichen Albinoratten für 6 Monate mit 
halbsynthetischen Diäten gefüttert, die entweder eine defiziente (<1 mg α-Tocopherol-
Äquivalente (αTÄ)/kg Diät), marginale (9 mg αTÄ/kg Diät) oder adäquate (18 mg αTÄ/kg 
Diät) Versorgung mit Vitamin E gewährleisteten; eine vierte Gruppe wurde mit einer Diät 
gefüttert, die mit natürlichem αT angereichert war (Vitamin E Gehalt insgesamt: 
146 mg αTÄ/kg Diät). 
Die α-Tocopherolgehalte in Leber, Cortex und Plasma stiegen in Abhängigkeit von den in 
den Diäten enthaltenen Vitamin E-Konzentrationen an. Die Responsivität der Gewebe 
hinsichtlich αT Depletion bzw. Anreicherung unterschied sich signifikant voneinander. Die 
Aufnahme der Vitamin E defizienten Diät über einen Zeitraum von 6 Monaten führte nahezu 
vollständig zur Depletion von αT in der Leber, jedoch nicht im Gehirn. Damit 
übereinstimmend wurden weder Veränderungen der F2-Isoprostan-Konzentrationen, der 
Expression von Hämoxygenase 1 (HO-1), der Aktivitäten antioxidativer Enzyme oder der 
Glutathionkonzentration in den Gehirnen der Vitamin E-defizienten Ratten beobachtet. Des 
weiteren kam es zu keinen Veränderungen in den mRNA Spiegeln Alzheimer-relevanter 
Gene zwischen den einzelnen Gruppen. In den Lebern der Ratten, welche Vitamin E defizient 
ernährt wurden, konnten, im Gegensatz zu den Tieren, welche adäquat mit Vitamin E ernährt 
wurden, signifikant erhöhte HO-1 mRNA- und Proteinkonzentrationen gemessen werden. 
In jüngster Zeit werden Mikro-RNA (miRNA) als post-transkriptionelle Genregulatoren 
diskutiert. Defiziente Versorgung mit Vitamin E führte, im Vergleich zu adäquater 
Versorgung, zu einer Abnahme der relativen Konzentrationen von miRNA-122a, welche eine 
Rolle im Fettstoffwechsel spielt, und von miRNA-125b, die an Entzündungsreaktionen und 
Krebsentstehung beteiligt ist. Diese Ergebnisse sind möglicherweise erste Hinweise für einen 
Einfluss von Vitamin E auf die Regulation hepatischer miRNA in vivo. 
Die vorliegenden Versuchsergebnisse zeigen, dass die Aufnahme steigender Konzentrationen 
an Vitamin E über einen Zeitraum von 6 Monaten die mRNA Konzentrationen in Gehirn und 
Leber der Ratte gewebespezifisch modulieren. Des weiteren wird postuliert, dass die 
genregulatorische Aktivität von Vitamin E sowohl durch Veränderungen der mRNA- als auch 
der miRNA- Konzentrationen vermittelt werden kann. 
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5α-R1 5-α-steroid reductase type 1 
Abeta amyloid β peptide 
AChE acetylcholinesterase 
AD Alzheimer’s disease 
ADAM-10 a disintegrin and metalloprotease domain 10 
AGE advanced glycation endproduct 
APP amyloid beta (A4) precursor protein 
Apba1 APP binding family member 1 
αTE α-tocopherol equivalents 
αTTP α-tocopherol transfer protein 
BACE-1 beta-site APP cleaving enzyme 1 
αTE alpha tocopherol equivalents 
Bax Bcl2-associated X protein 
Bcl-2 B-cell leukemia/lymphoma 2 
BHT butylated hydroxytoluene 
CD36 
 
Scavenger receptor CD36 
dVE vitamin E-deficient 
ECE endothelin-converting enzyme 
fVE vitamin E-fortified 
γGCSm 
 
regulatory subunit gamma-glutamylcysteinyl synthetase 
GSH glutathione 
HDL 
 
high-density lipoproteine 
HO-1 heme oxygenase 1 
IC50 concentration at which activity is 50% of control 
IDE insulin-degrading enzyme 
LDL 
 
low-density lipoprotein 
miRNA micro RNA 
mRNA messenger RNA 
mVE marginal vitamin E 
nt nucleotides 
PCR polymerase chain reaction 
PKC protein kinase C 
RNA ribonucleic acid 
RNAse ribonuclease 
SeGPx selenium dependent glutathione peroxidase 
SOD superoxide dismutase 
sVE vitamin E sufficient 
RISC RNA-induced silencing complex 
T tocopherol 
VE vitamin E 
VLDL 
 
very low-density lipoprotein 
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Molecular structure of vitamin E 
Vitamin E (VE) is the generic term for a group of eight lipid-soluble substances, named 
tocopherols (T) and tocotrienols, respectively, that are composed of a chromanol ring, bearing 
a free hydroxyl group, attached to a 16-carbon saturated phytyl (tocopherols) or unsaturated 
isoprenoid side chain (tocotrienols). The tocopherols and tocotrienols are further subdivided 
into α-, β-, γ-, δ- tocopherols and -tocotrienols depending on the number and positions of 
methyl groups attached to the chromanol ring (Figure 1). The three chiral centres at positions 
2, 4’ and 8’ give rise to eight different stereoisomers (RRR, RSR, RRS, RSS, SRR, SSR, 
SRS, SSS) for each tocopherol. Tocotrienols only have one chiral centre at position 2, and can 
therefore exist in R- or S-configuration. However, the double bonds at the 3’ and 7’ positions 
of the tocotrienol side chain give rise to four cis/trans geometrical isomers. Hence, 
theoretically eight isomers are possible for each tocotrienol (Kamal-Eldin & Appelqvist, 
1996). 
Naturally occurring tocopherols exist exclusively as RRR-stereoisomers, whereas synthetic 
tocopherols are composed of a racemic mixture (all rac), containing equal amounts of all eight 
stereoisomers (Kamal-Eldin & Appelqvist, 1996). 
 
 
 
 
 
   Tocopherol 
 
 
 
 
   Tocotrienol 
 
Figure 1: Chemical structures of tocopherols and tocotrienols. 
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Dietary sources and intake of vitamin E 
Natural tocopherols and tocotrienols are exclusively synthesized by photosynthetic organisms 
i.e. plants and some cyanobacteria. Plants accumulate αT mainly in their green tissues, while 
tocotrienols are predominantly found in the bran and germ fractions of certain seeds and 
cereals (Kamal-Eldin & Appelqvist, 1996). Vegetable oils are the richest sources of 
vitamin E, with wheat germ, safflower, and sunflower oils being particularly rich in αT, and 
soybean, corn, and sesame oils in γT. Other good sources of VE include lipid-rich plant parts 
such as nuts, seeds and grains. Tocotrienols are present at high concentrations in palm, rice-
bran, and coconut oils and soybeans (Packer et al., 2001). Compared to other Western 
populations, where αT is the predominant form in the diet, γT is the major dietary form of VE 
in the USA because of the widespread use of soybean and corn oils (Wagner et al., 2004). 
 
Rapeseed oil, a natural food source for vitamin E 
Rapeseed oil, because of its fatty acid composition with a high percentage of 
monounsaturated fatty acids, its high content of the polyunsaturated ω-3 fatty acid α-linolenic 
acid (Table 1), and its high concentrations of natural vitamin E (Table 2), is considered to be 
of great nutritional value (Schöne et al., 1998). 
 
Table 1: Fatty acid compositions of various vegetable oils (Kamal-Eldin & Andersson, 1997). 
 Fatty acids (% of total fatty acids) 
Oil type 16:0 16:1 18:0 18:1 18:2 18:3 
Cottonseed 23.0 0.0 2.3 15.6 55.6 0.3 
Linseed 5.6 0.0 3.2 17.7 15.7 57.8 
Olive 13.8 1.4 2.8 71.6 9.0 1.0 
Palm 44.8 0.0 4.6 38.9 9.5 0.4 
Rapeseed 4.6 0.3 1.7 60.1 21.4 11.4 
Sesame 9.6 0.2 6.7 41.1 41.2 0.7 
Soybean 10.1 0.0 4.3 22.3 53.7 8.1 
Sunflower 5.2 0.1 3.7 33.7 56.5 0.0 
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Table 2: Tocopherol contents of selected oils, margarines, seeds, nuts, and cereals (Wagner et al., 2004). 
Ordered by α-tocopherol concentration. 
Tocopherols, mg/100 g 
Products 
α  β γ  δ  
Oils     
 Wheat-germ 133 71 26 27 
 Sunflower1 49 - 5 0.8 
 Cottonseed 39 - 39 - 
 Rapeseed1 32 - 38 2 
 Palm 26 - 32 7 
 Sesame 14 - 29 - 
 Peanut 13 - 21 2 
 Olive 12 - 0.7 - 
 Corn2 11 5 60 1.8 
 Linseed 8 - 58 2 
 Soybean2 8 1.5 80 27 
Margarines (based on)     
 Sunflower oil1 6 - 10 3 
 Corn oil2 5 - 46 - 
 Soybean oil2 5 - 34 10 
Seeds     
 Sunflower seeds 50 3 - - 
 Sesame seeds - - 23 - 
Nuts     
 Almonds 45 19 - - 
 Pecan nuts - - 16 - 
 Peanuts 11 - 8 - 
 Brazil nuts 11 - 5 3 
Cereal grains     
 Rice, white 0.3 - 0.3 - 
 Sweet corn 0.2 - 4.5 - 
1Preferential consumption in Europe 
2Preferential consumption in the USA 
 
A rapeseed variety with especially high tocopherol concentrations (∼850 mg/kg total 
tocopherols) was developed by Norddeutsche Pflanzenzucht Hans-Georg Lembke KG 
(Holtsee, Germany) and kindly provided for the production of the rapeseed oil used in the 
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present experiments. For more information regarding the production of the rapeseed oil used 
in this thesis see chapter II. 
 
Absorption, distribution, and metabolism of vitamin E 
Vitamin E is comprised of a group of lipophilic substances and, as such, absorbed and 
transported in the body together with other food lipids. In the gut, vitamin E is incorporated 
into mixed micelles and taken up into the enterocytes. The efficiency of vitamin E absorption 
is in the range of 15-45% of the ingested dose, while the remainder is excreted with the faeces 
(Traber & Sies, 1996). The absorption of vitamin E was long thought to occur by passive 
diffusion (Kayden & Traber, 1993), but more recently, the ATP-binding cassette (ABC) 
transporter scavenger-receptor class B type I (SR-BI) was found to be involved in αT uptake 
(Reboul et al., 2006). In the enterocytes, vitamin E is incorporated into chylomicrons, which 
are secreted into the lymphatic system and then pass through the thoracic duct into the 
systemic circulation. Upon contact with lipoprotein lipase, an enzyme located on vascular 
endothelial cells, chylomicrons are catabolized to chylomicron remnants and a part of the 
transported vitamin E is transferred to extra hepatic tissues and other lipoproteins. With the 
chylomicron remnants, the remaining vitamin E reaches and is taken up into the liver (Kayden 
& Traber, 1993). 
The absorption and trafficking of tocopherols and tocotrienols does not differ for all eight 
vitamin E congeners until they reach the liver. In the liver, however, RRR-αT is preferentially 
incorporated in VLDL (very low density lipoproteins) over the non-RRR-α-tocopherols and 
tocotrienols, involving the action of α-tocopherol transfer protein (αTTP) (Kayden & Traber, 
1993). αTTP recognizes the fully methylated chromanol head and the R-configuration at 
carbon 2 (2R) (Meier et al., 2003). The binding affinities of αTTP for tocopherols and 
tocotrienols relative to that of RRR-αT have been determined as: βT, 38%; γT, 9%; δT, 2%; 
SRR-αT, 11%; and αT3, 12% (Hosomi et al., 1997).  
In the liver, non-αT congeners and, to a much lesser extent, excess αT are metabolized to 
side-chain truncated, water-soluble carboxyethyl hydroxychroman (CEHC) metabolites and 
eventually excreted in urine (Sontag & Parker, 2002). Tocopherols and CEHCs also undergo 
biliary excretion, although it is not known to what extent (Traber & Kayden, 1989; Kiyose et 
al., 2001). Initial ω-hydroxylation of the vitamin E side-chain appears to be facilitated by 
cytochrome P450 (CYP) enzymes and was reported to occur with a higher catalytic activity 
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towards the non-αT congeners, suggestive of a central role for the involved enzymes in the 
selective retention of αT in the body and the regulation of γT plasma concentrations (Sontag 
& Parker, 2002). Indeed, the selective accumulation of αT in the fruit fly Drosophila 
melanogaster, which does not express αTTP, has been associated with CYP activity (Parker 
& McCormick, 2005). Following ω-hydroxylation, side-chain shortening is facilitated by 
enzymes of the β-oxidation pathway (Sontag & Parker, 2002). 
From the liver, αT and to a lesser extent γT is secreted into the bloodstream, incorporated into 
very-low-density lipoproteins (VLDL). During VLDL catabolism, other lipoproteins become 
enriched with tocopherols and eventually deliver the vitamin to target tissues (Traber & Sies, 
1996). The largest fraction of VE is transported in low-density (LDL) and high-density 
lipoproteins (HDL), a smaller amount in VLDL (Behrens et al., 1982). Uptake into tissues is 
facilitated by either the LDL-receptor or, in the case of HDL-associated vitamin E, the 
scavenger receptor class B type I (SR-BI) (Qian et al., 2005). The rate at which absorbed 
vitamin E is taken up by the various tissues depends on the turnover of the respective tissue. 
Plasma and liver are tissues with a fast turnover, whereas in brain or neural tissues the 
turnover is slow (Burton & Traber, 1990). 
 
Biological functions of vitamin E 
Vitamin E was initially discovered, because its absence in the diet of female rats resulted in 
infertility caused by foetal resorption (Evans & Bishop, 1922). In the following decades, 
vitamin E deficiency syndromes were discovered and described for many species, including 
pigs, chicken, rats, and mice, but its essential biological function remained elusive (Mason, 
1977). After the discovery of the antioxidant properties of tocopherols (Olcott & Emerson, 
1937), this antioxidant activity was assumed to be the biological function of the vitamin in 
vivo (Dam, 1952). This assumption was driving vitamin E research for many decades, until 
presumed non-antioxidant functions of tocopherols, such as inhibition of protein kinase C 
(PKC) (Mahoney & Azzi, 1988) and regulation of cellular signal transduction pathways and 
gene expression (Rimbach et al., 2002) were discovered. However, the notion that αT might 
exert biological functions independent of its antioxidant activity is currently a matter of 
debate (Azzi, 2007; Traber & Atkinson, 2007). One group of researchers put forward the idea 
that αT or its derivative α-tocopheryl phosphate may act as cellular signalling molecules or 
redox sensors via binding to as yet unknown transcription factors or receptors (Azzi, 2007), 
while an opposing school of thought supports the notion that all biological activities exerted 
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by αT, including the regulation of gene expression and cellular signalling cascades, can be 
explained on the basis of its antioxidant protection of polyunsaturated fatty acids and the 
resulting effects on membrane qualities (integrity, fluidity, phase separation, etc.) (Traber & 
Atkinson, 2007). The most important discoveries in vitamin E research are summarized in 
Table 3. 
 
Table 3: Milestones in vitamin E research. 
Year Milestone 
1922 Evans and Bishop discovered a then unknown essential factor for the successful 
reproduction of rats, which they called substance “X” (Evans & Bishop, 1922) 
1925 This substance “X” was assigned its vitamin status and named “E”, because of 
the earlier discovery of the vitamins A-D (Mason, 1977) 
1936 An alcohol preventing female sterility and foetal resorption in rats was isolated 
from wheat germ oil by Evans and co-workers and named α-tocopherol, from 
the Greek word “tokos” (child birth), “phero” (to bear), and the suffix “ol” 
indicating an alcohol (Evans et al., 1936). 
1968 The RDA for vitamin E was established at 300 mg (300 IU) for a 65 kg adult 
male (Food and Nutrition Board, 1968; Food and Nutrition Board) 
1982 Burton, Joyce, and Ingold claim the first proof that VE is the major lipid-soluble 
chain-breaking antioxidant in human blood plasma (Burton et al., 1982) 
1988 α-Tocopherol was shown to inhibit protein kinase C activity (Mahoney & Azzi, 
1988) 
1991 Purification and characterization of αTTP (Sato et al., 1991) 
1993 Primary structure of αTTP (Sato et al., 1993) 
1998 The expression of the αTTP gene in the liver is induced by αT and δT (Fechner 
et al., 1998) 
1999 Supernatant protein factor (SPF), a protein stimulating cholesterol biosynthesis, 
was shown to be identical with α-tocopherol-associated protein (TAP) (Stocker 
et al., 1999) 
2000 RDA values were replaced by Dietary Reference Intakes (DRI); the DRI were 
set at 15 IU for both men and women (Food and Nutrition Board, 2000) 
2001 αT identified as a transcriptional regulator of gene expression by binding of 
TAP (Yamauchi et al., 2001) 
2001 The first use of αTTP-/- mice as a genetic model of vitamin E-deficiency 
(Terasawa et al., 2000) 
2002 Crystal structure of the human TAP was reported (Stocker et al., 2002) 
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Antioxidant function 
Free radicals are highly reactive atoms, molecules or ions capable of autonomous existence 
with at least one unpaired electron. Free radicals and other reactive species can damage 
biological molecules, such as membrane lipids, nucleic acids and proteins, thereby starting 
radical chain reactions (Ames et al., 1993). Lipid peroxidation proceeds via such a self-
propagating chain reaction, which can be subdivided into initiation, propagation and 
termination, unless stopped by formation of stable products through the reaction of two 
radicals with each other or of a radical with an antioxidant (Kamal-Eldin & Appelqvist, 
1996). 
  
Initiation: R• + LH → RH + L• 
Propagation: L• + O2 → LOO• 
   LOO• + LH → LOOH + L• 
Termination: L• + TOH → LH + TO• 
   TO• + LOO• → LOO-TO 
 
R• = free radical species, L = lipid, TOH = tocopherol, TO• = tocopheroxyl radical 
 
 
Barry Halliwell defined an antioxidant as: “any substance that, when present at low 
concentrations compared to those of an oxidizable substrate, significantly delays or prevents 
oxidation of that substrate” (Halliwell, 1990). 
Oxidative and reductive processes are elemental in metabolism, during which highly reactive 
free radicals are generated as by-products of the energy production in the respiratory chain. 
The organism also employs free radicals to kill exogenous cells as part of its immune defence 
(Halliwell, 1990). VE protects lipids against oxidative damage, especially polyunsaturated 
fatty acids (PUFA) in the lipid phase of biomembranes and in plasma lipoproteins. VE 
incorporates into (cell) membranes, where it reacts with free radicals by donating hydrogen 
atoms, thereby breaking the membrane-damaging free radical reaction. The thus formed VE 
radical is much less reactive and does not efficiently react with nearby macromolecules. The 
in vitro antioxidant capacities (that is, the chemicophysical reactivities) of the tocopherols and 
tocotrienols depend on the number of methyl groups substituted at the chromanol head. The 
abilities of the different tocochromanols to donate hydrogen atoms increase with the number 
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of methyl substituents in the order: αT > βT > γT > δT (Kamal-Eldin & Appelqvist, 1996). In 
vivo, however, the situation is more complex. In the body, the antioxidant capacities of the 
VE congeners do not only depend on their chemical reactivities, but also on factors such as 
absorption, transport, metabolism, excretion, and compartmentalisation. Therefore, the fully 
methylated congeners with 2R-stereochemistry are recognized as the most important in vivo 
antioxidants (Kamal-Eldin & Appelqvist, 1996). In agreement, VE, and in particular αT, was 
identified as the major lipid-soluble antioxidant in human plasma (Burton et al., 1982). 
 
Regulation of cellular signalling and gene expression 
In 1988, Mahoney and Azzi (1988), with their finding of a reduced protein kinase C (PKC) 
activity in the presence of very high concentrations of αT (IC50, 456 µmol/L αT), were the 
first to suggest a role of αT in cellular signalling pathways. Three years later, the same group 
discovered that αT inhibits PKC activity in vascular smooth muscle cells resulting in growth 
arrest. This effect was specific for αT, whereas βT, trolox (a synthetic tocopherol analogue) 
and αT esters had no such effect. Furthermore, the effect occurred at concentrations of αT 
that are physiological in healthy adults (25 µM) (Boscoboinik et al., 1991). Subsequently, the 
mechanism of action was found to involve the dephosphorylation of PKC by activated protein 
phosphatase 2A (Ricciarelli & Azzi, 1998). Since the original finding in 1988, other functions 
of αT related to cellular signalling and gene expression have been revealed. In vitro and in 
vivo experiments demonstrated that αT inhibits monocyte-endothelial cell adhesion (Devaraj 
et al., 1996), platelet adhesion and aggregation (Freedman et al., 1996; Williams et al., 1997) 
and cyclooxygenase 2 activity (Wu et al., 2001). 
Some of the above mentioned studies conclude that the observed effects of αT were 
independent of its antioxidant activity, despite lacking a proper control treatment that would 
support such a conclusion. The use of βT as control, for example, in cell culture experiments 
(Fazzio et al., 1997; Breyer & Azzi, 2001) neglects the known differences regarding the 
metabolism of αT and βT (see above), which may result in rapid catabolism of βT and thus 
significant differences in the cellular (and thus active) concentrations of αT and βT (Sontag & 
Parker, 2002). 
Supplementation with vitamin E (primarily αT) was shown to regulate the expression of 
several genes at the transcriptional level, including genes that are i) involved in the uptake and 
degradation of tocopherols, ii) implicated with lipid uptake and atherosclerosis, iii) involved 
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in the modulation of extracellular proteins, iv) connected to adhesion and inflammation, and 
v) implicated in cell signalling and cell cycle regulation (classification according to Azzi et al. 
2004; Table 4). 
Gene regulation may also occur as a result of vitamin E depletion: VE deficiency increased 
rat liver γGCSm and γGCSc (catalytic subunit) and decreased p21 (cyclin-dependent kinase 
inhibitor 1A) mRNA concentrations (Morante et al., 2005). Furthermore, VE deficiency 
increased mRNA concentrations of HO-1 (heme oxygenase 1), a gene with cytoprotective 
functions (Ito et al., 1997). 
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Global gene expression profiling with DNA microarrays  
In order to obtain a comprehensive understanding of the biological processes in which 
vitamin E is involved, global gene expression profiling with DNA microarray technology was 
utilized to understand the consequences of chronic VE deficiency in laboratory rats and mice 
in a number of tissues including hippocampus (Rota et al., 2005), cortex (Hyland et al., 2006), 
heart (Vasu et al., 2007), lung (Oommen et al., 2007), liver (Barella et al., 2004; Rimbach et 
al., 2004), skeletal muscle (Nier et al., 2006), testes (Barella et al., 2004; Rota et al., 2004), 
and prostate (Siler et al., 2004), as summarized in Table 5. 
 
Table 5: Effects of α-tocopherol depletion on tissue specific transcriptomes and associated biological processes. 
Analyses from gene chip experiments. 
 
Tissue 
 
 
Associated biological processes as a result of α-tocopherol depletion 
 
 
Hippocampus 
 
− Hormones/hormone metabolism 
− Neuronal survival 
− Dopaminergic system 
− Amyloid beta/ advanced glycation endproduct clearance 
 
Cortex 
 
− Neuronal signal transduction 
 
Heart 
 
− Lipid metabolism 
− Inflammation 
 
Lung 
 
− Cytoskeleton 
 
Liver 
 
− Androgen metabolism 
− Blood coagulation 
− Redox homeostasis 
− Inflammation 
 
Skeletal muscle 
 
− Muscle structure 
− Inflammation 
− Growth/development 
 
Testes 
 
− Testosterone synthesis 
− Cholesterol homeostasis 
− Androgen metabolism 
 
Prostate 
 
− Androgen metabolism 
− Estrogen metabolism 
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Post-transcriptional gene regulation 
Ribonucleic acids (RNA) can be subdivided into coding RNA (messenger RNA, mRNA) and 
non-coding RNA (transcriptional RNA and small RNA) (Buckingham, 2003) (Figure 2). 
 
 
 
 
 
 
Figure 2: Classification of RNA family members. Abbreviations: mRNA, messenger RNA; rRNA, ribosomal 
RNA; tRNA, transfer RNA; siRNA, small interfering RNA; miRNA, micro RNA; snoRNA, small nucleolar 
RNA; snRNA, small nuclear RNA  (Buckingham, 2003). 
 
During the processes of gene transcription and translation, in addition to coding RNA, the 
organism makes use of a number of RNA that do not code for a peptide but serve other 
molecular functions. A number of these non-coding RNA, such as ribosomal and transfer 
RNA, which effectuate the ribosomal assembly of peptides, have been known for decades. 
Small interfering RNA (siRNA) such as microRNA (miRNA), on the other hand, are 
relatively recent discoveries and facilitate post-transcriptional gene-silencing by a process 
named RNA interference (RNAi, reviewed in Rana, 2007). miRNA are short, double-stranded 
RNA species comprised of ∼19-25 nucleotides (nt) that are encoded in the genome and 
transcribed by an RNA polymerase into long (hundreds to thousands of nt) primary miRNA. 
GENERAL INTRODUCTION 
 16 
Primary miRNA are cut by the ribonuclease (RNase) Drosha and its co-factor Pasha into 
stem-loop structured precursor miRNA (pre-miRNA) of ∼70 nt length, which are shuttled 
from the nucleus to the cytoplasm by Exportin 5, where they are further processed by the 
RNase Dicer into small (∼22 nt) miRNA. These mature miRNA are unwound and one strand 
– the so-called guide strand – is loaded into the RNA-induced silencing complex (RISC), a 
multi-protein complex containing known (including argonaute and Dicer) and as yet unknown 
proteins, while the other strand – the passenger strand – appears to be degraded. Several of 
these miRNA-loaded RISC complexes then bind to the target mRNA at the 3’ untranslated 
region, inhibit its translation and direct it toward processing bodies (P-bodies), where it may 
be stored or degraded. The exact fate of the target mRNA is determined by the degree of base 
complementarity between the miRNA and its target mRNA. Perfect complementarity 
activates the siRNA pathway that causes complete degradation of the target mRNA and 
involves the RNase in RISC. Gene-silencing via the siRNA pathway is mainly observed in 
plants and to a much lesser extent in animals. Imperfect base complementarity triggers the 
miRNA pathway, which results in the inhibition of gene translational at the initiation or 
elongation step and/or in partial RNA degradation through destabilisation due to poly(A)-
shortening of the transcript (Cowland et al., 2007; Rana, 2007) (Figure 3).  
It has been computed that each miRNA binds on average ∼100 different target mRNAs, thus a 
single miRNA could, at least theoretically, facilitate post-transcriptional silencing of many 
different genes. It was calculated that ∼30% of the genes of the vertebrate genome might be 
under the regulation of miRNA (Lewis et al., 2005).  
 
While there is ample evidence showing that VE affects gene expression by altering mRNA 
transcription (Barella et al., 2004; Rimbach et al., 2004), at present, nothing is known about 
the effects of dietary VE on the expression of miRNAs (see also chapter IV). 
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Figure 3: Biogenesis and processing of, and gene-silencing by micro RNA (modified from Kosik, 2006).  
miRNA are genomically encoded and transcribed by an RNA polymerase into long primary miRNA (pri-
miRNA), which are cleaved by the ribonuclease Drosha and its cofactor Pasha into a 70-100 nucleotide 
precursor (pre-miRNA) with stem-loop structure. The pre-miRNA is translocated from the nucleus by exportin 
5, an evolutionary conserved nuclear export factor (Bohnsack et al., 2004), into the cytoplasm, where it is 
cleaved by an enzyme complex including the proteins Dicer and loquacious. The resulting miRNA duplex is 
then unwound by a helicase, releasing a guide and a passenger strand. The guide strand is translocated to the 
RNA-induced silencing complex (RISC) where it binds to a target mRNA, leading to either degradation (perfect 
binding to the mRNA) or reduced translation (non-perfect binding to the mRNA), while the passenger strand is 
destroyed (Bartel, 2004; Kosik, 2006). 
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Vitamin E and neuroprotection 
Life expectancy and the number of people aged >60 years, and in parallel with this, the 
number of people suffering from age-related neurological disorders, are constantly increasing 
in industrialised countries (Fratiglioni et al., 2000). Alzheimer’s disease (AD), also known as 
Morbus Alzheimer, is the most common neurodegenerative disorder affecting the brain. 
Clinical symptoms include progressive loss of memory and reduced cognitive ability. The 
underlying histological changes in the brain include the extra-cellular accumulation of 
amyloid β peptide, resulting in so-called amyloid plaques, and the formation of intra-cellular 
neurofibrillary tangles consisting of hyper-phosphorylated tau protein. The characteristic 
pathophysiological hallmarks of AD are synaptic dysfunction, massive progressive loss of 
neurons by apoptosis, especially in the hippocampus and cortex, and a selective depletion of 
neurotransmitter systems (e.g. acetylcholine) (Leuner et al., 2007). 
On the cellular level, the processes leading to neuronal death and, thus, neurodegenerative 
events and AD, are caused by or result in an increased formation of reactive oxygen and 
nitrogen species. Such an imbalance between free radical generation and elimination is 
termed “oxidative stress” and was causally connected with the incidence of AD (Lin & Beal, 
2006). Epidemiological studies indicate that a high intake of vitamin E from food sources, but 
not from dietary supplements, may contribute to the prevention of age-related 
neurodegenerative disorders such as AD (Engelhart et al., 2002; Morris et al., 2002; Morris et 
al., 2005). Morris and colleagues evaluated the contribution of the different vitamin E 
congeners toward the prevention of AD. While a higher dietary intake of both αT and γT was 
associated with a decreased risk of developing AD, their data suggested that the combination 
of the different vitamin E congeners may be more effective in preventing AD than the intake 
of αT alone (Morris et al., 2005). In line with this, another epidemiological study (Fillenbaum 
et al., 2005) did not find a delayed onset of dementia after vitamin E supplementation. Zandi 
and co-workers (2004) demonstrated, that vitamin E and vitamin C in combination are more 
effective in reducing AD incidence. 
Some clinical intervention studies employing high dosage αT supplements, on the other hand, 
found a significant reduction in AD progression (Sano et al., 1997; Onofrj et al., 2002), while 
in another study by Petersen and colleagues (2005), supplementation of high doses of αT 
failed to slow down the progression of AD (Table 6). 
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Table 6: Clinical intervention trials studying the role of vitamin E in the prevention of Alzheimer’s disease. 
Reference VE dose and 
duration 
Study design Conclusion 
(Sano et al., 
1997) 
2000 IU/day 
2 years 
341 patients 
double-blind, placebo-controlled, 
randomized, multicenter study; AD patients, 
matched healthy controls 
VE slowed 
progression of AD 
(Onofrj et al., 
2002) 
2000 IU/day 
6 months 
60 patients 
randomized, controlled clinical trial 
VE delayed onset of 
AD 
(Petersen et 
al., 2005) 
2000 IU/day 
3 years 
212 mild cognitive impairment 
double-blind, placebo-controlled 
no effect of VE on 
AD progression 
 
Findings from human intervention trials are supported by observations from animal studies 
where vitamin E altered physiological processes relevant for the progression as well as the 
prevention of AD. Gene chip technology was used to identify vitamin E-sensitive genes that 
play an important role in the prevention of AD by global gene profiling in laboratory rats 
(Rota et al., 2005). The authors reported the modulation by vitamin E of mRNA 
concentrations of genes that are involved in the clearance and stabilization of the neurotoxic 
amyloid β peptide. The aggregation of amyloid β is a molecular key event in the pathogenesis 
of AD and responsible for the formation of so-called senile plaques. Furthermore, vitamin E 
significantly altered the transcription levels of genes that inhibit programmed cell death 
(apoptosis) and, thereby, loss of neurons (Rota et al., 2005). 
At present, no effective therapies are available for the treatment of AD, therefore research into 
the prevention of the disease is of high importance. Because of the association of 
neurodegenerative disorders with increased levels of oxidative stress, the neuroprotective 
activities of natural antioxidants and especially of vitamin E deserve further attention.  
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Aim 
The overall aim of the present thesis was to investigate the influence of vitamin E from a 
natural source on gene expression in the brain and liver of laboratory rats. Rapeseed oil was 
chosen as a rich source of natural vitamin E. The production of the rapeseed oils and 
experimental diets used in the feeding trial are presented in detail in chapter II. In chapter III, 
the impact of long-term feeding of graded dietary doses of natural-source vitamin E on 
tocopherol concentrations, parameters of oxidative stress, and the expression of AD-relevant 
genes in cortex and hippocampus is described. Chapter IV presents the impact of vitamin E 
depletion on the expression of selected hepatic miRNAs in rats. In chapter V, the presented 
experiments and data are discussed in the context of the current literature. 
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Oil production 
S-NAP 944 is a rapeseed variety rich in αT, which was developed within the project 
NAPUS 2000 and was provided by Dr. Leckband (Norddeutsche Pflanzenzucht Hans-Georg 
Lembke KG (NPZ)). Pressing of the oil was carried out by Pilot Pflanzenoeltechnologie 
Magdeburg e.V. (PPM e.V.). Rapeseeds underwent an initial quality check and were mature, 
without stocking, with medium- to large-sized grains, and a neutral to rapeseed-typical odour. 
Seeds were flaked on roller mills to increase the oil yield. Warm-pressing usually results in a 
higher oil yield, but also in the formation of undesirable by-products, which make subsequent 
refining necessary. Refining, however, causes thermal degradation of vitamin E and, thus, 
decreases the tocopherol content of the resulting oil (Willner et al., 1997). To ensure a 
maximum vitamin E-yield during oil production, S-NAP 944 rapeseeds were cold-pressed 
under nitrogen atmosphere. The crude oil was of strong yellow-green colour and vacuum-
filtered to increase stability, after which it was gold-yellow and had a rapeseed oil-typical 
smell. 
 
Purification of the oil and removal of vitamin E and other natural antioxidants 
The cold-pressed rapeseed oil was stripped of tocopherols and other antioxidants by 
adsorption chromatography according to the method of Lampi and Kamal-Eldin (1992). 
Aluminium oxide (250 g) was activated at 100°C for 8 h and at 200°C for 12 h. Glass 
columns (60 x 3 cm) were plugged with wads of cotton, which were soaked with n-hexane. 
Proper care was taken to avoid the inclusion of air in order to prevent oxidation at the bottom 
of the column before putting aluminium oxide. The activated aluminium oxide (stationary 
phase, adsorbent) was suspended with n-hexane (mobile phase) and the suspension was filled 
into the glass columns. The columns were capped with cotton to exclude air and to prevent 
stirring of the stationary phase during application of the oil. The eluent n-hexane was drained 
until the liquid level was ca. 1 cm above the top cotton wad. The prepared column was free of 
fissures and air bubbles. In order to avoid exposure of the oils to light, the column was 
wrapped in aluminium foil and dark glass jars were used for the collection of the stripped oils. 
Rapeseed oil was mixed 1:1 (v/v) with n-hexane (500 ml each) and applied to the column. 
Approximately 300 ml n-hexane was used to elute the remaining oil, after the oil-hexane-
mixture had passed through the column. Finally, the stripped rapeseed oil was purged with a 
stream of nitrogen gas and stored at -20°C until analysis and removal of hexane. The absence 
of tocopherols from the purified oils was verified by HPLC. Therefore, 100 mg oil were 
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weighed into caps, 400 µl n-heptane (with 1 mg/ml BHT) were added, the mix was vortexed 
and injected into the HPLC (column: LiChrosphere Si 100, 5 µm, 10 x 250 mm; mobile 
solvent: n-heptane/isopropanol 100:1; flow rate: 1,0 ml/min; λExcitation: 290 nm; 
λEmission: 328 nm). 
Hexane was removed from the stripped oil in a vacuum rotary evaporator with the water bath 
initially set to 65°C. For the last 10 minutes, the water temperature was increased to 90°C. 
Subsequently, the oil was purged with a stream of nitrogen gas and stored at -20°C until 
further use. 
 
Figure 1: Flow chart of the oil preparation and tocopherol concentrations in the resulting oils. 
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Preparation of oils with different vitamin E concentrations 
In order to obtain oils with increasing vitamin E concentrations, the stripped and native oils 
were blended at varying ratios (1:0, 1:1, 0:1; v/v; Figure 1). The native oil was fortified with 
RRR-α-tocopherol to prepare a fourth oil with a particularly high content of alpha-tocopherol. 
 
Fatty acid composition of the native and stripped oils 
Vitamin E, carotinoids, and other antioxidants as well as free fatty acids and mono- and 
diglycerides were adsorbed at the stationary phase during column chromatography and thus 
removed from the oil. Because fatty acids affect gene expression (Sessler & Ntambi, 1998; 
Jump et al., 2005), the fatty acid profiles of the prepared oils were determined by gas 
chromatography (column: DB-WAX; detector: GC-FID). As shown in Figure 2, the fatty acid 
profiles of the rapeseeds, the native rapeseed oil, and the stripped rapeseed oil did not differ 
significantly. 
 
 
Figure 2: Fatty acid profiles of rapeseed variation S-NAP 944, its native and stripped oil. 
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Preparation of the animal diet 
The composition of the semi-synthetic experimental diets is shown in Table 1. The prepared 
rapeseed oils were used as the sole source of fat and tocopherols in the diets. All diets were 
cold-palletized and vacuum-packed with oxygen absorber pads in polyethylene bags in units 
of 1.5 kg. Diets were stored at -20°C until used. 
 
Table 1: Composition of the diets used in the feeding experiment. 
Compound g/kg diet 
Casein 240 
Corn starch, modified 480 
Glucose 110 
Cellulose powder Arbocell B 800 50 
Vitamin E-free vitamin premix (E15313-2) 10 
Mineral premix (E15000) 60 
Rapeseed oil* 50 
*All vitamin E in the diet originated from the rapeseed oil. Vitamin E concentrations of the 
diets prepared with tocopherol-stripped oil, tocopherol-stripped oil plus native oil (blended at 
a ratio of 1:1), native oil or α-T-fortified oil (4 g RRR-α-T/kg native oil) were <1, 9, 18 or 
146 mg/kg diet, respectively (see Chapter III). 
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ABSTRACT 
Oxidative stress is one of the major pathological features of Alzheimer’s disease (AD). Here 
we investigated whether dietary vitamin E depletion may induce adverse effects and 
supplementation with alpha tocopherol (αT) may result in beneficial effects on redox status 
and the regulation of genes relevant in the pathogenesis of AD in healthy rats. Three groups 
of 8 male rats each were fed diets with deficient (<1 mg αT equivalents (αTE)/kg diet), 
marginal (9 mg αTE/kg diet) or sufficient (18 mg αTE/kg diet) concentrations of natural-
source vitamin E for 6 months; a fourth group was fed the VE sufficient diet fortified with αT 
(total vitamin E, 146 mg αTE/kg diet). Feeding of the experimental diets dose-dependently 
altered αT concentrations in cortex and plasma. No significant changes in F2-isoprostane 
concentrations, activities of antioxidative enzymes (total SOD, SeGPx) and concentrations of 
glutathione, or the expression of AD-relevant genes were observed. In this non-AD model, 
depletion of vitamin E did not induce adverse effects and supplementation of αT did not 
induce positive effects on parameters related to the progression of AD. 
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INTRODUCTION 
Oxidative stress appears to be centrally involved in the pathogenesis of Alzheimer’s disease 
(AD) and many of the pathological processes involved in its development and progression are 
either caused by or lead to an augmented generation of reactive oxygen and nitrogen species 
(Christen, 2000). Therefore, the importance of vitamin E for the maintenance of neuronal 
integrity and brain function is becoming increasingly recognized. 
Epidemiological studies indicate that a high intake of vitamin E from food sources, but not 
from dietary supplements, may contribute to the prevention of age-related neurodegenerative 
disorders such as AD (Morris et al., 1998; Engelhart et al., 2002; Morris et al., 2005). Morris 
and colleagues evaluated the contribution of the different vitamin E congeners towards the 
prevention of AD. While a higher dietary intake of both α-tocopherol (αT) and γ-tocopherol 
(γT) was associated with a decreased risk of developing AD, their data suggested that the 
combination of the different vitamin E isoforms may be more effective in preventing AD than 
the intake of αT alone (Morris et al., 2005). In line with this, in some intervention studies 
supplementation of high doses of αT, the major lipid-soluble antioxidant in human plasma 
and the vitamin E congener with the highest biological potency (Food and Nutrition Board of 
the Institute of Medicine, 2000), failed to delay the onset of dementia (Fillenbaum et al., 
2005) and to slow down the progression of AD (Petersen et al., 2005). Other clinical 
intervention studies employing high dosage αT supplements, on the other hand, found a 
significant reduction in AD progression (Sano et al., 1997; Onofrj et al., 2002). 
Little is known regarding the long-term effects of dietary vitamin E on the expression of 
genes involved in the development or prevention of AD and on the antioxidant status in the 
healthy brain. The aim of the current study was therefore to investigate (i) if suboptimal 
supply of dietary vitamin E may cause unfavorable physiological changes with regard to 
parameters of oxidative stress and the expression of genes relevant in the pathogenesis of AD 
in the healthy brain and (ii) whether supplementation of a high dose of αT on top of an 
already sufficient dietary supply of vitamin E may induce AD-preventive effects. 
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MATERIALS AND METHODS 
Experimental diets 
The tocopherol-rich rapeseed variety S-NAP 944 (a gift from Norddeutsche Pflanzenzucht 
Hans-Georg Lembke KG, Holtsee, Germany) was cold-pressed under a nitrogen atmosphere. 
The resulting oil was vacuum-filtered and contained 341 mg αT, 386 mg γT and 11 mg δT 
per kg oil. A part of the native rapeseed oil was stripped of tocopherols by column 
chromatography as described by Lampi et al. (1992). The fatty acid composition of the oil 
(oleic acid, 49.1% of total fatty acids; linoleic acid, 19.7%; linolenic acid, 10.8%; erucic acid, 
7.2%; gadoleic acid, 4.9%; palmitic acid, 4.5%) was not altered by the removal of 
antioxidants (data not shown). The tocopherol-stripped oil was used (i) unmodified or (ii) 
blended at a ratio of 1:1 with the native oil, (iii) the native oil was used unaltered or (iv) 
fortified with 4 g natural RRR-α-tocopherol (Cognis, Monheim am Rhein, Germany) per kg 
oil. Butylated hydroxytoluene (Carl Roth GmbH, Karlsruhe, Germany; 200 mg/kg) was added 
to all oils as a preservative to protect the tocopherols from oxidative decay.  
These oils were used to prepare diets (ssniff Spezialdiaeten GmbH, Soest, Germany) with 
vitamin E concentrations that, according to the Nutrient Requirements of Laboratory Rats 
(1995), can be classified as vitamin E-deficient (dVE), -marginal (mVE), -sufficient (sVE), 
and -fortified (fVE). 
The composition of the four semi-synthetic experimental diets was as follows (g/kg diet): 
casein, 240; corn starch, modified, 480; glucose, 110; cellulose, 50; vitamin E-free vitamin 
premix (E15313-2), 10; mineral premix (E15000), 60; rapeseed oil, 50. All vitamin E in the 
experimental diets originated from rapeseed oil and were as follows (as analyzed by HPLC 
and given in mg/kg diet): dVE: αT, <1; γT, <1; mVE: αT, 6; γT, 11; sVE: αT, 12; γT, 24; and 
fVE: αT, 140; γT, 24. 
 
Experimental animals and study design 
The animal experiment was conducted in accordance with the German regulations on animal 
care and with permission of the responsible authority. Thirty-two male Fisher 344 rats 
(Charles River Laboratories, Sulzfeld, Germany) with a mean initial body weight of 51±5 g 
were randomly divided into 4 groups of 8 animals each and fed the experimental diets for 6 
months. The rats were housed in Macrolon III cages in a conditioned room (22±2°C, 55% 
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relative humidity, 12 h light-dark cycle). The animals had free access to tap water and the 
experimental diets throughout the experiment. Food consumption and animal weight were 
recorded daily and weekly, respectively. At the end of the experiment, the rats were fasted for 
12 h prior to CO2-anaesthesia and decapitation. Blood samples were collected in tubes 
containing heparin as anticoagulant and plasma was obtained by centrifugation (4°C, 3000 x 
g, 10 min) and stored at -80°C until analyzed. The brain was excised and dissected; one part 
of the cortex and the hippocampus were stored in RNAlater (Qiagen, Hilden, Germany). The 
remaining brain was snap-frozen in liquid nitrogen and stored at -80°C. 
 
Quantification of tocopherols 
Tissues (100 mg) were weighed into test tubes with screw caps on ice. Ethanol (2 ml) 
containing 1% (by weight) ascorbic acid, 700 µl H2O, and 300 µl saturated aqueous KOH 
were added. The samples were saponified at 70°C in a shaking water bath for 30 min, and 
then cooled on ice. Fifty µl BHT in ethanol (1 mg/ml) and 2 ml n-hexane were added, and the 
samples were centrifuged (4°C, 5 min, 167 x g) to aid phase separation. One ml of the 
supernatant were transferred to a clean tube and dried under a stream of nitrogen gas. The 
residue was dissolved in 250 µl mobile phase (methanol:water (98:2, v/v)) and injected into 
the HPLC system. Plasma samples (100 µl) were processed as described above, but without 
saponification. Tocopherols were analyzed using a Jasco (Gross-Umstadt, Germany) HPLC 
system (pump PU2080Plus, autosampler AS2057Plus, detector FP2020Plus). The separation 
of tocopherols was performed on a Waters Spherisorb ODS-2 column (100 mm x 4.6 mm, 3 
µm). The fluorescence detector was set to an excitation wavelength of 296 nm and emission 
wavelength of 325 nm. The concentrations of α- and γ-tocopherols were quantified by use of 
authentic tocopherols (Calbiochem, Schwalbach, Germany) as external standards (limit of 
quantification, ≈ 50 pg). Analyses were performed in duplicate. Porcine plasma with known 
concentrations of αT and γT was analyzed in parallel as quality control. Plasma vitamin E 
concentrations were normalized for plasma cholesterol concentration, which was determined 
spectrophotometrically using a commercial kit (Fluitest® CHOL 4241, Biocon Diagnostik, 
Voehl/Marienhagen, Germany) according to the manufacturer’s protocol. 
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Determination of rat cortex concentrations of F2-isoprostanes 
Cortex samples were homogenized using Dounce homogenizer to yield 10% homogenates in 
180 mM KCL, 10 mM EDTA, 0.1 mM BHT, pH 7.4. To hydrolyse esterified F2-isoprostanes, 
the cortex homogenates (100 µl) were treated with 4 M KOH at 45oC for 30 min and 
neutralized by addition of 4 M HCl (pH adjusted to 2.0 with 0.1 M HCl). 0.5 nanogram of 
9α,11α-PGF2α-d4 (Cayman Chem. Co., Ann Arbor, MI) was used as an internal standard. 
Fatty acids, inclusively isoprostanes, were extracted two times by ethylacetate. The samples 
were centrifuged for phase separation and the upper phases were applied onto NH2 cartridges. 
Solid phase extraction and derivatisation steps were performed as previously described 
(Wiswedel et al., 2004). F2-Isoprostanes were separated and measured by gas 
chromatography/ negative-ion chemical ionization mass spectrometry (DSQ/Trace GC Ultra, 
Thermo Fischer Scientific, Dreieich, Germany) with ammonia as reagent gas using selected 
ion monitoring of the carboxylate anion [M-181] at m/z 569 and m/z 573 for F2-isoprostanes 
and the deuterated internal standard. The F2-isoprostane peak co-eluted with authentic 8-iso-
PGF2α, but it is known that other F2-isoprostane isomers occur at the same retention time 
(Morrow et al., 2002). All analyses were performed in triplicate for each tissue sample. The 
protein content was determined using the method of Bradford (Bradford, 1976). 
 
Antioxidant enzyme activities and glutathione concentration in the cortex 
Cortex tissue (100 mg) was diluted 1:10 (by weight) in ice-cold phosphate-buffered saline 
(PBS) and homogenized. The homogenate was centrifuged (3000 x g, 4°C, 10 min), the 
supernatant collected and used for the measurements after appropriate dilution in PBS. 
Superoxide dismutase (total SOD) enzyme activity was measured according to the method of 
Marklund and Marklund (1974). Se-dependent glutathione peroxidase (SeGPx) activity was 
measured according to the method of Lawrence and Burk (1976) using bovine GPx (Sigma 
Aldrich, Darmstadt, Germany) to generate the external standard curve. GSH concentrations 
were measured in homogenates according to Tietze (1969) with modifications  (Dringen & 
Hamprecht, 1996). All measurements were carried out on a DU 800 spectrophotometer 
(Beckman Coulter, Krefeld, Germany). Results for antioxidant enzyme activities and GSH 
concentrations were adjusted for protein content as assessed using a commercial kit (BCA 
Protein Assay; Pierce, Rockford, IL, USA). 
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RNA isolation and real-time qRT-PCR 
Total RNA was extracted according to the RNeasy® Lipid Tissue Protocol (Qiagen). DNA 
digestion was performed with the RNase-Free DNase Set (Qiagen). The concentration of 
isolated RNA was spectrophotometrically determined (Beckmann Instruments; Munich, 
Germany) by measuring the absorbance at 260 nm, the purity was determined by the ratio of 
260/280 nm and a ratio of 1.6-1.9 was considered as acceptable. RNA aliquots were stored at 
-80°C until PCR analysis. Primer sequences for real-time RT-PCR experiments were 
designed with Primer3 software (version 0.4.0; http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3_www.cgi). Primer pairs (Table 1) were obtained from MWG Biotech 
AG (Ebersberg, Germany). The Bcl-2 primer was obtained from Qiagen. One-step 
quantitative reverse transcriptase PCR was carried out with the QuantiTect™ SYBR® Green 
RT-PCR kit (Qiagen). Real-time PCR amplification was performed in a Rotor-Gene 3000 
thermocycler (Corbett Research, Sydney, Australia). Relative mRNA concentrations of genes 
were quantified by use of a standard curve. Target gene mRNA concentration was normalized 
to the mRNA concentration of the housekeeping gene β-actin. 
 
Table 1: Nucleotide sequences of primers used for the real-time qRT-PCR experiments. 
Gene  Primer sequence forward (5’-3’)  Primer sequence reverse (5’-3’)  
β-Actin  GGG GTG TTG AAG GTC TCA AA  TGT CAC CAA CTG GGA CGA TA  
APP  CAG CGT GTC ATC CCA AAG T  GCG TGC TCG TTC TCA TCT C  
Apba1  AGC AGT AAG CCG GAT CAA GA  GAT CCT CTG GGT GGA GAT GA  
ADAM-10  GGG CAA TGT GCA GGT TCT AT  TGA ACT GCT TGT TCC ACT GC  
BACE-1  AAT CAG TCC TTC CGC ATC AC  GGC TCG ATC AAA GAC CAC AT  
ECE CTA TGT CAG TGC CGA CTC CA CCC AGC TGG ACC ATG TAG TT 
IDE TCA AAG GGC TGG GTA AAC AC CCT TGC ACT CTT GGA AAA CC 
NEP ACC TAG CAG GTG GAC AGC AT ACA CCT GGG CAA AGT TCA AG 
Bax  AGC TGC AGA GGA TGA TTG CT  GAT CAG CTC GGG CAC TTT AG  
AChE  CAG CAA TAC GTG AGC CTG AA  TTC CAG TGC ACC ATG TAG GA  
αTTP GCT TTT CAA ATT ACC CCA TC GAT CCC ACG AAC TTT CAA TG 
HO-1 GGG TGA CAG AAG AGG CTA AG GCT GAT CTG GGA TTT TCC TC 
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Western blot experiments in cortex homogenates 
Cortex tissue (100 mg) was homogenized in RIPA buffer (NaCl, 150 mM; sodium 
deoxycholate, 0.5%; SDS, 0.1%; NP-40, 1%; EDTA, 20 mM; Tris-HCl, 50 mM, pH 7.4; 
DTT, 1mM; protease inhibitor cocktail). Lysates were purified by centrifugation (4°C, 14000 
x g, 30 min). Total protein concentrations in each lysate were quantified using a BCA Protein 
Assay Kit (Pierce). Total proteins of the lysate (40 µg per lane) were separated by SDS gel 
electrophoresis followed by transferring the proteins to a PVDF membrane, which were then 
blocked for 1.5 h in blocking buffer (5% non-fat milk in Tris-buffered saline (TBS)). Primary 
antibodies were diluted in 5% non-fat milk (Bax, Bcl-2, 1:200; β-actin, 1:1000) and the blots 
were incubated over night at 4°C. The blots were washed and incubated with secondary 
antibody (Santa Cruz Biotechnology; anti-mouse horseradish peroxidase) in blocking buffer 
(Bax, Bcl2, 1:5000; β-actin, 1:1000) with gentle agitation for 1 h at room temperature. The 
blots were washed and exposed to Immun-Star Western Chemiluminescent Kit (Bio-Rad 
Laboratories, Hercules, CA, USA) and scanned with a Chemidoc (Bio-Rad). Digital images 
were captured and quantified using the Quantity-One system (Bio-Rad). Relative 
concentration of proteins were quantified as the ratio between the amount of target protein 
and the amount of the housekeeping protein β-actin. 
 
Statistical analysis 
Statistical calculations were conducted with SPSS Version 13.0 (SPSS, Munich, Germany). 
For the comparison of group means, one-way ANOVA was performed with the Scheffé test 
(normal distribution, homogeneity of variances) or the Games-Howell test (normal 
distribution, heterogeneity of variances) as post-hoc tests. When data were not normally 
distributed, Mann-Whitney-U-test was performed. Significance was accepted at P<0.05. 
 
RESULTS 
Feed intake and bodyweight gain 
Total feed intake (data not shown) and final bodyweights (dVE, 362.8 g ± 11.5 g; mVE, 
366.6 g ± 18.3 g; sVE, 372.1 g ± 21.2 g; fVE, 349.9 g ± 21.0 g; means ± SD) did not differ 
between the dietary groups. 
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Plasma and tissue concentrations of α- and γ-tocopherols 
Plasma concentrations of total cholesterol were significantly lower in the dVE group than in 
the mVE (P<0.05) and fVE (P<0.001) groups (dVE, 2.23±0.22 mmol/L; mVE, 2.6±0.24 
mmol/L; sVE, 2.51±0.17 mmol/L; fVE, 2.80±0.24 mmol/L as means ± SD; one-way ANOVA 
with Scheffé post-hoc test) and were used to normalize plasma tocopherol concentrations. 
Consumption of the experimental diets with graded concentrations of VE for 6 months 
significantly and dose-dependently affected αT concentrations in plasma, lung, muscle, 
cortex, and hippocampus of male Fisher 344 rats (Table 2). 
 
Table 2: Effect of tocopherol intake on tocopherol concentrations in rat plasma, lung, muscle, cortex, and 
hippocampus. 
Tissue  Diet   
 dVE mVE sVE fVE P less than 
Plasma  n=8 n=8 n=8 n=8  
(nmol/ml)      
αT 0.34 ± 0.01A 10.8 ± 0.49B 17.7 ± 0.43C 38.1 ± 1.26D 0.001 
γT 0.01 ± 0.001A 0.57 ± 0.01B 0.55 ± 0.02B 0.07 ± 0.01C 0.001 
(nmol/mol cholesterol)      
αT 0.15 ± 0.002A 4.15 ± 0.09B 7.05 ± 0.15C 13.6 ± 0.18D 0.001 
γT <0.01A 0.22 ± 0.01B 0.22 ± 0.01B 0.02 ± 0.002C 0.001 
Lung (nmol/g)      
αT 0.40 ± 0.04A 12.1 ± 0.39B 21.2 ± 1.24C 43.1 ± 1.21D 0.001 
γT 0.04 ± 0.02A 0.54 ± 0.02B 0.65 ± 0.03C 0.09 ± 0.02A 0.05 
Muscle (nmol/g)      
αT 0.39 ± 0.04A 7.37 ± 0.28B 11.4 ± 0.64C 20.0 ± 0.92D 0.001 
γT 0.03 ± 0.004A 0.21 ± 0.01B 0.36 ± 0.03C 0.06 ± 0.005D 0.05 
Cortex (nmol/g)      
αT 3.78 ± 0.44A 16.7 ± 0.97B 21.2 ± 1.27B 30.0 ± 1.59C 0.001 
 n=8 n=8 n=6 n=8  
γT 0.01 ± 0.001A 0.13 ± 0.01B 0.16 ± 0.01B 0.05 ± 0.005C 0.001 
Hippocampus (nmol/g) n=7 n=6 n=5 n=6  
αT 2.00 ± 0.39A 7.86 ± 1.60A,B 9.64 ± 1.30B,C 15.6 ± 1.52C 0.05 
γT n.d.b n.d. n.d. n.d.  
 
a: n=number of observations; values represent means ± SEM. Values within each row not 
sharing a common superscript roman letter are statistically different at P. 
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F2-Isoprostanes and antioxidant enzymes in the cortex 
Concentrations of F2-isoprostanes in cortex homogenates were not significantly different 
between the dietary groups (Figure 1). 
 
 
Figure 1: F2-isoprostane concentrations (ng/mg protein) in the cortex of Fisher 344 rats fed the experimental 
diets for 6 months. Values are means ± SEM, n=8 per group. No statistical differences were observed. 
 
Superoxide dismutase and glutathione peroxidase activities as well as glutathione 
concentrations in the cortices of the rats were similar in all groups (Table 3). 
 
Table 3: Antioxidant enzyme activities and glutathione concentrations in the cortex.
*
 
 Antioxidative  enzymes 
Experimental groups SOD 
(U/mg protein) 
SeGPx 
(mU/mg protein) 
GSH 
(nmol/mg protein) 
dVE 13.8 ± 0.77 88.0 ± 4.67 24.9 ± 1.40 
mVE 13.0 ± 0.79 95.6 ± 5.20 25.1 ± 0.76 
sVE 13.5 ± 0.51 90.4 ± 4.35 23.9 ± 0.76 
fVE 14.2 ± 0.55 98.0 ± 6.61 26.0 ± 0.49 
*Values are means ± SEM, n=8 per group. No statistical differences were observed. 
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Gene expression in cortex and hippocampus 
In cortex and hippocampus, the differences in dietary  supply with vitamin E did not result in 
significant changes in relative mRNA concentrations of APP (amyloid beta (A4) precursor 
protein), Apba1 (APP binding family member 1), ADAM-10 (a disintegrin and 
metalloprotease domain 10), BACE-1 (beta-site APP cleaving enzyme 1), ECE (endothelin-
converting enzyme), IDE (insulin degrading enzyme), NEP (neprilysin), Bax (Bcl2-associated 
X protein), Bcl-2 (B-cell leukemia/lymphoma 2), AChE (acetylcholinesterase), αTTP (α 
tocopherol transfer protein), and HO-1 (heme oxygenase 1) (Table 4). 
 
Table 4: Relative mRNA expression (related to the housekeeping gene β-actin) of Alzheimer’s disease relevant 
genes in cortex and hippocampus. 
Experimental group 
Gene 
dVE mVE sVE fVE 
Cortex     
APP 1.21 ± 0.06 1.13 ± 0.08 1.13 ± 0.10 1.21 ± 0.04 
Apba1 1.06 ± 0.11 1.13 ± 0.11 1.35 ± 0.14 1.16 ± 0.09 
ADAM-10 0.94 ± 0.08 0.91 ± 0.08 1.06 ± 0.06 0.97 ± 0.08 
BACE-1 0.96 ± 0.07 0.88 ± 0.09 1.06 ± 0.08 0.98 ± 0.08 
Bax 0.94 ± 0.04 0.89 ± 0.07 1.08 ± 0.07 0.96 ± 0.03 
Bcl-2 1.09 ± 0.05 1.04 ± 0.05 1.16 ± 0.07 1.14 ± 0.05 
ECE 1.03 ± 0.06 0.87 ± 0.05 1.10 ± 0.09 0.96 ± 0.04 
IDE 0.92 ± 0.04 0.86 ± 0.07 1.07 ± 0.06 0.97 ± 0.08 
Neprilysin 1.58 ± 0.29 1.18 ± 0.30 1.25 ± 0.17 1.12 ± 0.06 
αTTP 1.06 ± 0.06 1.08 ± 0.09 1.17 ± 0.11 1.10 ± 0.06 
HO-1 1.35 ± 0.09 1.39 ± 0.10 1.45 ± 0.13 1.31 ± 0.11 
AChE 1.35 ± 0.23 1.04 ± 0.09 1.11 ± 0.06 1.27 ± 0.10 
 
Hippocampus 
    
APP 0.89 ± 0.08 0.88 ± 0.04 1.01 ± 0.08 0.95 ± 0.07 
Apba1 0.94 ± 0.06 0.92 ± 0.06 0.95 ± 0.08 0.95 ± 0.06 
ADAM-10 0.90 ± 0.06 0.83 ± 0.03 1.00 ± 0.04 0.83 ± 0.05 
BACE-1 0.79 ± 0.06 0.79 ± 0.03 0.76 ± 0.04 0.73 ± 0.02 
Bax 1.02 ± 0.08 0.84 ± 0.03 0.90 ± 0.02 0.90 ± 0.04 
Bcl-2 1.15 ± 0.08 1.01 ± 0.04 1.15 ± 0.05 1.08 ± 0.05 
ECE 0.95 ± 0.06 0.90 ± 0.04 0.95 ± 0.04 0.89 ± 0.05 
IDE 0.93 ± 0.12 0.88 ± 0.07 0.99 ± 0.08 0.86 ± 0.09 
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Table 4 (continued)    
Neprilysin 0.88 ± 0.07 0.98 ± 0.06 0.94 ± 0.05 0.89 ± 0.05 
αTTP 0.99 ± 0.07 0.91 ± 0.04 1.01 ± 0.09 1.02 ± 0.05 
HO-1 0.85 ± 0.10 0.68 ± 0.06 0.81 ± 0.05 0.63 ± 0.04 
AChE 0.96 ± 0.06 1.02 ± 0.10 1.05 ± 0.06 0.94 ± 0.07 
 
 
Protein concentrations of apoptosis markers in cortex homogenates 
Protein concentrations of Bcl-2 and Bax in the cortex did not differ between the groups 
(Figure 2). Protein concentrations of activated caspases 3 and 8 were undetectable (data not 
shown). 
 
 
Figure 2: Bcl-2, Bax and β-actin protein concentration in cortex homogenates (A). β-Actin served as 
endogenous (loading) control. Relative concentration of Bcl-2 and Bax (B). Values are means ± SEM, n=6. 
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DISCUSSION 
Epidemiologic as well as clinical intervention studies indicate that a high intake of vitamin E 
may be important for the prevention of age-related neurodegenerative disorders such as AD 
(Grundman et al., 2002). Of the different tocopherols present in foods, RRR-α-tocopherol 
(RRR-αT) is thought to be the most important to human health and has the highest vitamin E 
activity in humans and animals (Food and Nutrition Board of the Institute of Medicine, 2000). 
Plant oils are the major dietary source of tocopherols and rapeseed oil, due to its high 
concentrations of tocopherols and ω-3 fatty acids (Grusak & DellaPenna, 1999), is considered 
of high value for human nutrition. Therefore, in the present study, we investigated the effects 
of graded dietary concentrations of vitamin E from rapeseed oil on the antioxidant status and 
the regulation of genes relevant in the pathogenesis of AD in the brains of Fisher 344 rats 
during growth and maturation. During the 6 months-feeding period of the present experiment, 
no differences in feed intake and life weight gain were observed between the dietary groups, 
which is in accordance with our previous findings (Barella et al., 2004). 
 
VE in plasma and tissues 
In correspondence with the intake of αT, we observed dose-dependent changes in the 
concentrations of αT in brain (cortex and hippocampus), plasma and other tissues in our rats 
(Figure 1). In accordance with data from previously published rat experiments (Vatassery et 
al., 1988; Martin et al., 1999), the changes in αT concentrations in the brain, however, were 
less pronounced than the changes observed in all other tissues. Similarly, in Parkinson’s 
disease patients who, over a period of 5 months, consumed high amounts of αT (from 400 
IU/d during the first month to 4000 IU/d during the last month of supplementation), Pappert 
and colleagues observed large increases in αT concentrations in plasma (from 19 to 
111 µmol/l) while its concentrations in ventricular cerebrospinal fluid (CSF) remained 
unchanged (in a range of 0.114-0.164 µmol/l) (Pappert et al., 1996). 
In our rats, a deficient supply of αT (<1 mg/kg diet) resulted in an almost complete depletion 
of αT in the plasma (0.15±0.002 mmol/mol cholesterol), while again changes in the brain 
were less pronounced (Table 2). In the cortex and hippocampus, 3.7±0.4 and 2.0±0.4 nmol 
αT/g tissue, respectively, were retained even after 6 months of deficient vitamin E intake. 
These data are in agreement with the results of Clement et al. (1995), who fed rats from 
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vitamin E deficient mothers a vitamin E-deficient diet for 8 weeks, and observed a marked 
reduction in the concentrations of αT in serum, liver, and muscle, while significant 
concentrations of αT were preserved in all analyzed nervous tissues. Vatassery et al. (1988) 
observed that even though other tissues could be almost completely depleted of αT by feeding 
of a VE-deficient diet for 4 months, in the brain low levels of αT were retained. Combined, 
these results and ours suggest that the brain is especially efficient at maintaining αT within a 
certain physiological range, preventing both excessive αT accumulation as well as its 
depletion. 
In this study, the dVE, mVE, and sVE diets provided increasing concentrations of αT and γT. 
The fVE diet, on the other hand, was prepared by addition of αT to the natural rapeseed oil 
and thus provided the same amount of γT as the sVE diet but ~10x more αT. With decreasing 
γT concentrations in the dVE, mVE, and sVE diets, we observed dose-dependent decreases in 
the concentrations of γT in lung, muscle and cortex tissue but not in plasma. Interestingly, the 
fVE-fed rats consuming additional αT, also had significantly reduced plasma and tissue γT 
concentrations compared to sVE-fed rats despite a similar γT intake (Table 2). In humans, the 
phenomenon of reduced γ-T concentrations caused by a high intake of αT, was first described 
by Handelman and co-workers. In 86 subjects (>50 years of age, mean age 71.8±6.4), 
Handelman and colleagues observed an inverse relationship between αT and γT concentration 
in the plasma. Supplementation of 8 volunteers (30-60 years of age) with 1200 IU all-rac-αT 
per day for 8 weeks resulted in a significant increase of plasma αT and a significant decrease 
in γT (Handelman et al., 1985). These findings were later confirmed in humans by other 
researchers (Melchert & Pabel, 1998; Huang & Appel, 2003) and are thought to be the result 
of an induction of cytochrome P450 enzymes, which are involved in VE metabolism and 
preferentially degrade the desmethyl vitamers (Sontag & Parker, 2002), by αT. 
 
F2-Isoprostanes 
With increasing age, lipid peroxidation of membrane fatty acids in the brain appears to 
augment (Floyd & Hensley, 2002) and oxidative stress in the brain is thought to be an 
important factor in the pathology of AD (Grundman et al., 2002). Accordingly, concentrations 
of F2-iosprostanes, which are non-enzymatic free radical-induced peroxidation products of 
arachidonic acid (Morrow et al., 1990), have been found to be significantly higher in the CSF 
or brains of AD patients than those of matched healthy controls (Montine et al., 2004). We 
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investigated the effects of increasing doses of dietary VE on F2-isoprostane concentrations in 
the cortex of male Fisher 344 rats and found a non-significant trend towards higher F2-
isoprostane concentrations in the group fed the dVE diet, but overall no significant differences 
were observed between the dietary groups (Figure 1). Similar to our findings, Cuddihy and 
colleagues did not observe significant differences between the F2-isoprostane concentrations 
in the cortices of mice fed vitamin E-deficient or -sufficient diets for 40 weeks. Surprisingly, 
cortex concentrations of F4-neuroprostanes, which are oxidation products of docosahexaenoic 
acid (22:6), an abundant fatty acid in the brain, were positively correlated with αT 
concentrations (Cuddihy et al., 2008). 
Our results indicate that the low concentrations of αT retained in the brain may have been 
sufficient to protect the cortex from lipid peroxidation. 
Another aim of this study was to investigate whether or not the intake of different amounts of 
VE may influence the activity of antioxidative enzymes and modulate cellular glutathione 
levels. Activities of total SOD and SeGPx as well as concentrations of total GSH in the 
cortices of our rats did not differ between the experimental groups. It appears likely that the 
lack of oxidative stress in our animals may be responsible for the absence of differences in the 
activities and concentrations, respectively, of antioxidant enzymes. Supplementation with αT 
(fVE group) did not result in enhanced enzyme activities or concentration, either. However, 
there is no consistent opinion regarding this in the literature: while some groups report no 
changes of antioxidative enzyme activities or concentrations (Kolosova et al., 2006), others 
report increases in the activities or concentrations of antioxidant enzymes caused by vitamin 
E depletion (De & Darad, 1988) as well as supplementation (Devi & Kiran, 2004). 
 
Gene expression 
The accumulation and aggregation of misfolded proteins (particularly amyloid-β), the loss of 
neurons due to programmed cell death (e.g. apoptosis), and impaired neuronal signal 
transduction in specific parts of the brain are major pathological features of AD (Christen, 
2000). Therefore, we measured mRNA concentrations of genes involved in the formation 
(APP, Apba1, ADAM-10, BACE-1) or degradation (NEP, IDE, ECE) of amyloid-β, 
programmed cell death (Bcl-2, Bax), and neurotransmitter degradation (AChE) in the brains 
of our rats. 
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In cortex and hippocampus of our rats, dietary VE did not affect mRNA concentrations of the 
measured genes (Table 4). Some of the analyzed genes (e.g. AChE, BACE-1; (Melo et al., 
2003; Tong et al., 2005)) are thought to be regulated by oxidative stress, others experience 
age-related loss of activity and/or protein concentration (NEP, IDE; (Fukami et al., 2002; 
Caccamo et al., 2005)).  As an additional biomarker for oxidative stress, we determined heme 
oxygenase type 1 (HO-1) mRNA concentrations in the brains of our rats. HO-1 is 
up-regulated in situations of oxidative and nitrosative stress, presenting a cytoprotective effect 
against various forms of stress by releasing the vasoactive molecule carbon monoxide and the 
potent antioxidant bilirubin (Calabrese et al., 2003). A significantly higher expression of HO-
1 was observed in neurons and astrocytes of AD hippocampus and cerebral cortex samples 
relative to age-matched controls (Schipper et al., 1995). Consistent with our F2-isoprostane 
data, mRNA concentrations of HO-1 were not affected by VE depletion or supplementation, 
indicating the absence of oxidative stress in the rat brains in our study. 
αTTP mRNA has been found in the human and rat brains, although at lower concentrations 
than in the liver (Hosomi et al., 1998; Copp et al., 1999). The exact function of αTTP in the 
brain is not known, but it was suggested to function in maintaining αT concentrations in the 
brain (Leonard et al., 2002). In our study, αTTP mRNA concentrations were not changed by 
VE depletion or by αT supplementation. Other groups, however, observed that VE deficiency 
led to transcriptional alterations in the cortex (Hyland et al., 2006) and hippocampus (Rota et 
al., 2005) of rats as well as in αTTP-/- mice (Gohil et al., 2003). Rota and colleagues have 
shown that certain genes related to the pathophysiology of neurodegenerative diseases were 
regulated in rat hippocampi by dietary VE (Rota et al., 2005). One main difference between 
these two studies is that we fed our rats for 6 months, while Rota and colleagues fed theirs for 
9 months. In both studies, however, animals fed a VE deficient diet had significantly reduced 
VE concentrations in plasma and hippocampus, although the VE depletion of the brains 
remained incomplete, suggesting that the brain has a strong capability to retain VE. 
Additionally, the diets in our trial contained the synthetic antioxidant BHT to protect the diets 
from lipid peroxidation during storage and BHT may have exerted additional antioxidant 
effects in our rats by direct scavenging of reactive species and/or regenerating αT from its 
radical form (Frank et al., 2003). However, with 10 mg/kg, the concentration of BHT in our 
diets was low compared to 2000-4000 mg/kg diet employed in rat studies where antioxidant 
effects of BHT were observed (Kamal-Eldin et al., 2000; Frank et al., 2003). BHT is 
extensively metabolised in the liver and both BHT and its metabolites are excreted with the 
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bile, faeces and urine, which in turn results in a low rate of tissue accumulation of BHT 
(Daniel & Gage, 1965; Conacher et al., 1986; Thompson et al., 1991). Hence, potential 
antioxidant effects of BHT are likely to be more potent in the liver than in extra-hepatic 
tissues. However, hepatic HO-1 mRNA concentrations were significantly higher in the dVE 
than in the sVE animals in conjunction with reduced microRNA expression (Gaedicke et al., 
2008). Therefore, the absence of oxidative stress, as assessed by concentrations of F2-
isoprostanes and relative mRNA levels of HO-1, in the brains of our VE depleted as well as 
αT supplemented rats compared to control (sVE) is unlikely to be a result of the BHT in the 
diet. 
Apoptosis seems to be an important process in AD, as suggested by increased levels of 
apoptosis markers in the brains of AD patients (Honig & Rosenberg, 2000). Bcl-2 and Bax, 
anti- and pro-apoptotic members, respectively, of the Bcl-2 family of signaling molecules, 
play a central role in apoptotic cell death. Both proteins function independently to regulate 
cell death, but can also form heterodimers. Therefore, the ratio of Bcl-2 to Bax is indicative of 
a pro- or anti-apoptotic cell status (Lu et al., 2000). In our study, neither Bcl-2 nor Bax 
mRNA  (Table 4) and protein (Figure 2) concentrations were different depending on the diet. 
 
CONCLUSIONS 
The present data suggest that stepwise reduction of dietary αT and γT for 6 months does not 
impair antioxidant status, induce apoptosis or alter the expression of selected genes in the 
brains of rats. Similarly, αT supplementation of already VE sufficient animals does not 
improve antioxidant status, affect apoptosis or alter the expression of AD-relevant genes. In 
conclusion, VE does not appear to change parameters involved in the etiology and 
progression of AD in healthy animals. Further investigations into the impact of VE on these 
parameters in an AD disease model are warranted. 
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ABSTRACT 
 
Dietary vitamin E (VE) is known to regulate gene expression by altering mRNA 
concentrations. Recently, miRNAs have been discovered as a means of posttranscriptional 
gene regulation. Since the effect of  VE on miRNA regulation is unknown, we fed rats for 6 
months diets deficient or sufficient in VE and determined hepatic concentrations of miRNAs 
involved in processes previously associated with VE (lipid metabolism, miRNA-122a; cancer 
and inflammation, miRNA-125b). VE deficiency resulted in reduced concentrations of 
miRNA-122a and miRNA-125b. The findings of the present study demonstrate that 
differences in dietary VE may affect hepatic miRNA concentrations in vivo. 
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INTRODUCTION 
In rats, dietary vitamin E (VE), particularly its major congener α-tocopherol (αT), has been 
shown to regulate gene expression by increasing or lowering mRNA concentrations in various 
tissues (Ricciarelli et al., 2000; Barella et al., 2004; Rimbach et al., 2004; Rota et al., 2004; 
Hundhausen et al., 2006; Vasu et al., 2007). In mammals, mRNA levels often correlate poorly 
with the respective protein concentrations (Nelson & Keller, 2007). The recent discovery of 
microRNAs (miRNAs) revealed a possible explanation for this phenomenon. miRNAs are a 
class of small, non-coding, double-stranded RNAs that, in their mature form, are single-
stranded and ∼22 nucleotides long. Mature miRNAs post-transcriptionally suppress gene 
expression by binding at the 3’ untranslated region of mRNAs and inhibiting their translation 
into proteins (Boyd, 2008). It has been calculated that each miRNA binds on average 100 
different target mRNAs, allowing for post-transcriptional silencing of many different genes, 
or potentially entire pathways, by a single miRNA (Lewis et al., 2005). miRNA are encoded 
for in the genome and are, thus, liable to regulation. Presently, the potential regulatory effects 
of dietary VE on the expression of miRNAs are unknown. In order to investigate the role of 
dietary VE on miRNA expression, we fed rats for 6 months diets deficient or sufficient in VE 
and analyzed miRNA concentrations in the liver. For this study, we selected miRNAs that 
were previously shown to be involved in processes that have been associated with VE, 
namely lipid metabolism (miR-122a) (Esau et al., 2006; Kutay et al., 2006), cancer 
progression and inflammation (miR-125b) (Porkka et al., 2007; Sonkoly et al., 2007; Ozen et 
al., 2008). 
 
 
MATERIALS AND METHODS 
Experimental animals and diets 
Two groups of 8 recently weaned male Fisher 344 rats (mean body weight, 51±5 g; Charles 
River Laboratories, Sulzfeld, Germany) were randomly assigned to a vitamin E-containing 
(VE+) or a vitamin E-deficient diet (VE-). The composition of the semi-synthetic diets (ssniff 
Spezialdiaeten GmbH, Soest, Germany) was (g/kg diet): casein, 240; corn starch, modified, 
480; glucose, 110; cellulose, 50; vitamin E-free vitamin premix (E15313-2), 10; mineral 
premix (E15000), 60; rapeseed oil, 50. All vitamin E in the diets originated from native or 
antioxidant-stripped rapeseed oils, respectively, and were as follows (mg/kg diet; analyzed by 
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HPLC): VE-: αT, <1; γT, <1; VE+: αT, 12; γT, 24. Because consumption of oxidized lipids 
may alter gene expression (Koch et al., 2007), great care was taken to  protect the used oils 
and diets from oxidation. Peroxide values of the oils were <0.5 mEq O2/kg, indicating that no 
lipid oxidation had occurred. Butylated hydroxytoluene (Carl Roth GmbH, Karlsruhe, 
Germany; 200 mg/kg) was added to all oils as a preservative. Diets were vacuum-packed with 
oxygen absorber pads in polyethylene and stored at -20°C. The animals had free access to tap 
water and the experimental diets throughout the experiment and were housed in pairs in a 
conditioned room (temperature, 22±2°C; relative humidity, 55%; 12 h light/dark cycle). The 
animal experiment was conducted in accordance with the German regulations on animal care 
and with permission of the responsible authority. Food consumption was recorded daily and 
animal weight weekly. At the end of the experiment, the rats were fasted for 12 h prior to 
CO2-anaesthesia and decapitation. The liver was excised and dissected; one part was stored in 
RNAlater (Qiagen, Hilden, Germany) and the remainder snap-frozen in liquid nitrogen and 
stored at -80 °C until used. 
 
Quantification of tocopherols 
Tocopherols were quantified by HPLC with fluorescence detection as described by Augustin 
et al. (Augustin et al., 2008). 
 
Total RNA isolation 
Total RNA including miRNA were extracted by using the miRNeasy® Isolation Kit (Qiagen). 
DNA digestion was performed with the RNase-Free DNase Set (Qiagen). The concentration 
of isolated RNA was determined spectrophotometrically by measuring the absorbance at 
260 nm; purity was determined using the ratio of 260/280 nm and a ratio of 1.6-1.9 was 
considered acceptable. Total RNA aliquots were stored at -80°C until PCR or TaqMan 
analysis. 
 
Real-time qRT-PCR 
Primer sequences for real-time quantitative RT-PCR experiments were designed with Primer3 
software (version 0.4.0; http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi). Primer 
pairs (Table) were obtained from MWG Biotech AG (Ebersberg, Germany). One-step 
qRT-PCR was carried out with the QuantiTec® SYBR® Green RT-PCR kit (Qiagen). RT-PCR 
amplification was performed in a Rotor-Gene 3000 thermocycler (Corbett Research, Sydney, 
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Australia). Relative mRNA concentrations are given as the ratios between the amount of the 
target gene and the housekeeping gene β-actin. 
 
Table: Nucleotide sequences of primers used for the real-time qRT-PCR experiments. 
Gene  Primer sequence forward (5’-3’)  Primer sequence reverse (5’-3’)  
β-Actin  GGG GTG TTG AAG GTC TCA AA  TGT CAC CAA CTG GGA CGA TA  
CD36 AAG CAA GGT TGC CAT AAT TG CCA AAC ACA GCA TAG ATG GA 
5α-R1 TTA TGC TGA AGA CTG GGT GA AAA TAG TTG GCT GCA GAT ACG 
γ-GCSm TGT GTG ATG CCA CCA GAT TT GCT TTT CAC GAT GAC CGA GT 
αTTP GCT TTT CAA ATT ACC CCA TC GAT CCC ACG AAC TTT CAA TG 
HO-1 GGG TGA CAG AAG AGG CTA AG GCT GAT CTG GGA TTT TCC TC 
 
 
TaqMan analyses 
TaqMan® MicroRNA Assays were obtained from Applied Biosystems (ABI, Foster City, CA, 
USA). miRNA quantification was performed as two-step RT-PCR. Reverse transcription was 
performed in a thermocylcer (Biometra, Goettingen, Germany) with specific miRNA primers 
from the TaqMan® MicroRNA Assays and reagents from the TaqMan® MicroRNA Reverse 
Transcription Kit. During the PCR step, PCR products were amplified from cDNA samples 
using the TaqMan MicroRNA Assay together with the TaqMan® Universal PCR Master Mix 
(ABI). PCR reaction was performed in an Applied Biosystems 7300 Real-Time PCR System. 
Target sequences were as follows: hsa-miR-122a, UGGAGUGUGACAAUGGUGUUUGU; 
hsa-miR-125b, UCCCUGAGACCCUAACUUGUGA; hsa-miR-146a, 
UGAGAACUGAAUUCCAUGGGUU. Relative miRNA concentrations are given as the 
ratios between the amount of the target gene and the endogenous control snoRNA (rat). 
 
Western blot experiments in liver homogenates 
Liver tissue (100 mg) was homogenized in RIPA buffer, lysates were purified by 
centrifugation (4°C, 14000 x g, 30 min) and total protein concentrations in each lysate were 
quantified using a BCA Protein Assay Kit (Pierce). Total proteins of the lysate (40 µg per 
lane) were separated by SDS gel electrophoresis followed by transferring the proteins to a 
PVDF membrane. Samples were then incubated with the primary antibodies (diluted in 5% 
non-fat milk (1:1000)) and the secondary antibodies (Santa Cruz Biotechnology; anti-mouse 
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horseradish peroxidase) in blocking buffer (anti-HO-1, 1:4000; anti-β-actin, 1:1000). The 
blots were exposed to Immun-Star Western Chemiluminescent Kit (Bio-Rad Laboratories, 
Hercules, CA, USA) and scanned with a Chemidoc (Bio-Rad). Digital images were captured 
and quantified using the Quantity-One system (Bio-Rad). Relative concentration of proteins 
were quantified as the ratio between the amount of target protein and the amount of the 
housekeeping protein β-actin. 
 
Statistical analyses 
Statistical comparisons were made by means of a one-tailed unpaired t-test (normal 
distribution, homogeneity of variances), Welch-corrected t-test (heterogeneity of variances), 
or a Mann-Whitney U test (skewed data) as appropriate using the software Instat 3 for 
Macintosh (version 3.0b; GraphPad Software, Inc., San Diego, CA).  
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RESULTS AND DISCUSSION 
Neither symptoms of ataxia, a classical sign of severe VE-deficiency, nor differences in feed 
intake and life weight gain were observed in the animals fed vitamin E deficient (VE-) or VE-
sufficient (VE+) diets for 24 weeks (data not shown), which is in accordance with previous 
findings (Barella et al., 2004). As expected, hepatic αT concentrations were reduced in the 
VE- rats (Figure 1A), in agreement with the literature (Vatassery et al., 1988). 
 
 
 
 
Figure 1: Effect of dietary vitamin E on α-tocopherol concentrations in the liver (A) and plasma cholesterol 
concentrations (B) of rats fed vitamin E deficient (VE-) or sufficient (VE+) diets for 6 months. Values are 
expressed as means ± SEM, n=8. ***P<0.0001. 
 
 
Differences in hepatic αT were previously shown to affect relative mRNA concentrations in 
the liver of rats (Barella et al., 2004). In order to verify the differential expression of genes 
regulated by αT, we quantified relative mRNA concentrations of known VE sensitive genes 
in the livers of our rats. As expected, mRNA concentrations of CD36 and 5α-R1 were 
significantly increased, and mRNA concentrations of αTTP and γ-GCSm were significantly 
decreased in the VE- animals (Figure 2). 
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Figure 2: Effect of dietary vitamin E on (A) scavenger receptor CD36, (B) 5-α-steroid reductase type 1 (5α-
R1), (C) regulatory subunit gamma-glutamylcysteinyl synthetase (γ-GCSm), and (D) α tocopherol transfer 
protein (αTTP) mRNA concentrations in rat liver. Values are means ± SEM, n=8. **P<0.001, ***P<0.0001. 
 
 
Recently, miRNA have been discovered as molecules that effect post-transcriptional gene-
silencing by a process termed RNA interference (Rana, 2007). To date, the impact of dietary 
VE on hepatic miRNA concentrations is unknown. VE has long been investigated for its 
potential cardiovascular disease (CVD) and cancer preventive properties (Jialal et al., 2001; 
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Tucker & Townsend, 2005). Increased circulating concentrations of blood lipids, especially 
cholesterol, and pro-inflammatory cytokines have been associated with increased risk for 
CVD and cancer (Belluco et al., 2000; Scott, 2004). For the current investigations, we 
selected two miRNAs (122a, 125b) that were shown to regulate genes associated with lipid 
metabolism and cancer. Because miRNAs are evolutionary conserved across species, the 
chosen miRNAs are found in rat as well as in human tissue (Bartel, 2004). 
 
 
 
 
Figure 3: Effect of dietary vitamin E on miR-122a and miR-125b concentrations in rat livers. Values are means 
± SEM, n=8. *P<0.05, ***P<0.0001. 
 
 
miRNA-122 is liver-specific and the most abundant miRNA in the liver (Girard et al., 2008). 
In our rats, concentrations of miR-122a in the liver (Figure 3) and cholesterol in plasma 
(Figure 1B) were significantly lower in the VE- than in the VE+ group. Esau and co-workers 
(2006) used antisense oligonucleotide inhibition to specifically inhibit miR-122 in mice, 
which resulted in significantly increased hepatic concentrations of 108 mRNAs related to 
lipid metabolism and significantly reduced plasma cholesterol and triacylglycerol 
concentrations. A comparable experiment recently supported the finding that cholesterol 
concentrations are only weakly reduced upon targeted inhibition of miR-122, although a large 
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number of genes related to lipid metabolism were differentially regulated (Elmen et al., 2008). 
Apart from its role in lipid metabolism, miR-122 was down-regulated in rodent and human 
hepatocellular carcinomas (Kutay et al., 2006) and is thought to play a critical role in liver 
development (Chang et al., 2004).  Shan and colleagues demonstrated that inactivation of 
miR-122 by antagomir 122, a chemically synthesized oligonucleotide with sequence 
complimentary to miR-122, resulted in decreased Bach-1 and increased HO-1 mRNA 
concentrations (Shan et al., 2007). Bach-1 is a repressor of the redox-sensitive transcription 
factor nuclear factor erythroid 2-like 2 (Nrf2), which controls HO-1 expression (Reichard et 
al., 2007). In agreement, HO-1 mRNA as well as protein concentrations were increased in our 
VE deficient rats (Figure 4). Because oxidative stress is known to cause Nrf2 activation (Itoh 
et al., 2004), the induction of HO-1 expression in our rats might also have occurred by a miR-
122 independent mechanism. 
 
 
 
 
Figure 4: Effect of dietary vitamin E on (A) HO-1 mRNA concentration (values are means ± SEM, n=8, 
**P<0.001) and (B) protein levels of HO-1 and β-actin (loading control). Western blots of two representative 
animals per group are shown. 
 
 
Vitamin E-depletion in our rats caused significant, but relatively weak changes in miR-122a 
when compared to targeted inhibition (Esau et al., 2006; Elmen et al., 2008). In fact, dietary 
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factors are not expected to exert drastic effects on miRNA expression (Barella et al., 2004). 
Nevertheless, even small changes in hepatic miRNA expression over a prolonged period may 
be of biological significance. 
 
In our study, miR-125b was significantly down-regulated in the VE- as compared to the VE+ 
animals (Figure 3). A role for miRNA-125b in cancer development has been suggested 
because miRNA-125b was down-regulated in human prostate cancer tissues (Porkka et al., 
2007; Ozen et al., 2008), lung cancer cell lines (Nagayama et al., 2007), breast cancer (Iorio et 
al., 2005), and in squamous cell carcinoma of the tongue (Wong et al., 2008). Shi and 
colleagues (2007), on the other hand, found over-expression of miR-125b in prostate cancer 
cell lines and prostate cancer samples. Retroviral infection of the breast cancer cell line 
SKBR3 with constructs expressing 125b resulted in ca. 35% suppression of the oncogenic 
proteins ERBB2 and ERBB3 at the transcript as well as protein levels, and the cells exhibited 
reduced migration and invasion capacities (Scott et al., 2007). A role of miRNA-125b in 
inflammation is supported by a study that identified TNFα as a direct target of miRNA-125b. 
A decrease of miR-125b resulted in increased TNFα production and inflammation in LPS 
stimulated macrophages (Tili et al., 2007). Thus, the reduced miR-125b levels observed in our 
VE deficient rats may be associated with an enhanced inflammatory response due to vitamin 
E deficiency, as previously described (Lim et al., 2008; Yamaoka et al., 2008). 
 
In conclusion, in rats fed a VE-depleted diet for 6 months, VE deficiency resulted in reduced 
concentrations of miRNA-122a and miRNA-125b, which may play an important role in lipid 
metabolism, carcinogenesis, and inflammation. Thus, the gene regulating properties of α-
tocopherol may be, at least partly, mediated by changes in miRNA levels. 
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CHAPTER V 
 
GENERAL DISCUSSION 
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The present thesis aimed at studying the effects of vitamin E (VE) from the natural source 
rapeseed oil on the regulation of selected genes in the brain and liver of healthy rats. 
Rapeseed oil was chosen as source of vitamin E, because a high intake of vitamin E from food 
but not from dietary supplements was previously shown to contribute to the prevention of 
age-related neurodegenerative diseases (Engelhart et al., 2002; Morris et al., 2002; Morris et 
al., 2005). In the brain, the focus was set on genes relevant for the development and 
prevention of Alzheimer’s disease. In the liver, emphasis was placed on the effects of dietary 
VE on the expression of miRNAs, a group of regulatory RNAs that post-transcriptionally 
silence genes (see Chapter I). 
 
Vitamin E and neuroprotection 
Oxidative stress appears to play an important role in the pathogenesis of AD (see also 
Chapter I). Decreased vitamin E concentrations were found in the cerebrospinal fluid of AD 
patients compared to healthy controls (Kontush & Schekatolina, 2004).  Sano and co-workers 
(1997) demonstrated in a placebo-controlled trial, that the daily intake of 2000 IU vitamin E 
for 2 years could slow down the progression of the disease in patients with mild AD. A 
combined intake of vitamin E and C supplements resulted in a reduced prevalence and 
incidence of AD in a population aged 65 years and older (Zandi et al., 2004). In a transgenic 
AD mouse model, supplementation with vitamin E at an early stage reduced lipid 
peroxidation and amyloid beta deposits in the brain (Sung et al., 2004). Those trials indicate, 
that vitamin E intake may prevent or even slow down AD. Other trials, however, were not 
able to confirm these results. Supplementation of patients suffering from mild cognitive 
impairment (MCI) with 2000 IU/day vitamin E or placebo for 3 years did not result in 
significant differences in progression from MCI to AD (Petersen et al., 2005). 
While the brain makes up only 2% of the overall body weight, it has the highest oxygen 
uptake rate of all organs with approximately 20% of the whole bodies oxygen consumption 
(Smith et al., 1999). Given the fact that, within the mitochondrial electron transport chain, 2-
5% of the consumed oxygen is converted to superoxide, the brain is exposed to a constant 
flux of reactive species. The activities of antioxidant enzymes, such as catalase, superoxide 
dismutase and glutathione peroxidase, in the brain are only ∼10% of the activities in the liver 
and other tissues (Floyd, 1999). Because of its high content of polyunsaturated fatty acids 
(PUFA), such as arachidonic acid (C20:4) and docosahexaenoic acid (C22:6), the brain is 
particularly vulnerable to oxidative insult (Smith et al., 1999). F2-isoprostanes, for example, 
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are formed in vivo by non-enzymatic free radical-catalyzed peroxidation of arachidonic acid 
and contribute to inflammatory processes (Basu, 2008). Therefore, a sufficient supply of 
antioxidants, such as αT, is likely of particular importance for the brain.  
Not only oxidative, but also nitrative stress appears to play an important role in the 
pathogenesis of AD. Reactive nitrogen species can be formed by the reaction of nitric oxide 
with reactive oxygen species and elevated concentrations of nitric oxide have been found in 
brains of AD patients (Floyd & Hensley, 2002). The γT nitration product 5-nitro-γT as well as 
the protein nitration products 3-nitrotyrosine and 3,3’-dityrosine were elevated in cortical 
regions of brains from AD patients as compared to age-matched controls (Hensley et al., 
1998; Williamson et al., 2002). Due to its unsubstituted 5-position, γT but not αT is capable 
of scavenging reactive nitrogen species, thus reducing nitrative stress (Williamson et al., 
2002). Maintaining optimum γT concentrations may, thus, be of particular importance in the 
prevention of age related dementias. Because γT appears to have biochemical properties that 
may be important in the prevention of AD, a decrease in γT concentrations due to high αT 
intake, as observed in our rats (Chapter III, Table 2), might be unfavourable and may even 
partly explain the negative outcomes of high dosage αT supplementation trials. 
As outlined in the introduction (Chapter I), the lack of effective treatments for AD makes the 
prevention of the disease all the more important. Because of the observation that VE from 
food sources but not from supplements was associated with a reduced AD risk, we chose to 
study the effects of graded dietary doses of VE from a natural food source in a model 
simulating healthy and not demented subjects, as detailed in Chapter III. 
 
Vitamin E and the expression of Alzheimer’s disease-relevant genes 
In order to study the effects of dietary vitamin E on the pathology of AD, transgenic mouse 
models, such as Tg2576 (developing Aβ plaques), APP23 (neuronal cell loss) or TAPP 
(exhibiting both Aβ plaque and neurofibrillary tangle pathology) are frequently employed 
(Higgins & Jacobsen, 2003). Here, we chose the non-transgenic rat strain “Fisher 344” as a 
model animal, because the focus of the present work was on the prevention of oxidative stress 
and neurodegeneration as well as the expression of AD-associated genes rather than the 
interference with pathological processes in progress. 
Oxidative stress and the development of neurodegenerative diseases are tightly connected. 
Therefore, one aim of this study was to investigate the influence of vitamin E deficiency in 
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healthy animals on the occurrence of oxidative stress and its potential association with 
differential gene expression of Alzheimer’s disease relevant genes. The VE-dependent 
expression of these genes (see below) was studied in hippocampus and cortex, the tissues 
primarily affected by AD. 
Amyloid β (Aβ) is a 40-42 amino acid peptide that is formed by proteolytic cleavage of its 
precursor amyloid β precursor protein (APP) and is a major component of senile plaques, a 
characteristic hallmark of AD (Nunan & Small, 2000). APP processing and Aβ generation 
can be slowed down by interaction of APP with the APP-stabilizing protein amyloid β (A4) 
precursor protein-binding, family A, member 1 protein (Apba1), which can preserve APP 
from cleavage by secretases (Sastre et al., 1998). Initial cleavage of APP may be facilitated by 
one of two different secretases, namely α- or β-secretase, and is followed by a second scission 
through a γ-secretase. α-Secretase cleaves APP within the amyloid sequence, which precludes 
the formation of the amyloidogenic peptide Aβ and leads to the release of the neurotrophic, 
soluble APPsα into extracellular fluids following γ-secretase cleavage; APPsα represents a 
normal component of plasma and CSF (Lammich et al., 1999; Rota et al., 2005). Hydrolysis 
of APP by β-secretases prior to γ-secretase scission leads to the formation of the insoluble, 
neurotoxic Aβ. mRNA concentrations of the major secretases involved in Aβ formation, 
namely ADAM-10, as a member of the α-secretase family (Nunan & Small, 2000) and 
BACE-1, the major β-secretase, were quantified. Although it is not yet fully understood how 
ADAM-10 and BACE-1 are regulated, oxidative stress was suggested to be directly 
responsible for BACE-1 activation and, thereby, the production of Aβ (Tong et al., 2005). 
Under physiological conditions, Aβ is degraded by enzymes including neprilysin (NEP), 
insulin-degrading enzyme (IDE), and endothelin-converting enzyme (ECE), which all belong 
to a group of zinc-metallopeptidases. Diminished concentrations and activities of these 
enzymes may increase the risk for AD, whereas increases may be protective. 
Achetylcholinesterase (AChE) is an enzyme cleaving the neurotransmitter acetylcholine, 
which is produced by cholinergic neurons. In AD, loss of cholinergic neurons in the basal 
forebrain occurs and leads to a diminished production of acetylcholine and, thus, to impaired 
signal transduction. In order to prevent rapid neurotransmitter degradation, some AD 
treatments are directed at enhancing the cholinergic system by inhibiting AChE (Holzgrabe et 
al., 2007). Bond and Greenfield observed increased mRNA concentrations of AChE as a 
result of oxidative stress in astroglia (Bond & Greenfield, 2007). In agreement, Melo and 
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colleagues found increased AChE activity due to Aβ induced oxidative stress in cultured 
retinal cells and its reduction by pre-incubation with VE (Melo et al., 2003). 
In our model, neither dietary VE-depletion, nor supplementation with αT for 6 months 
resulted in the differential expression of the above-described genes involved in AD 
development (Chapter III , Table 4). 
 
Vitamin E and gene regulation 
In our study, mRNA concentrations of  HO-1, a biomarker of oxidative stress, were 
significantly increased in the liver of animals fed the dVE diet compared to the other groups, 
whereas in cortex and hippocampus of the same animals no changes in HO-1 mRNA 
concentrations were observed. In situations of oxidative and nitrosative stress, the expression 
of the enzyme HO-1, which acts as a cytoprotectant by releasing the vasoactive molecule 
carbon monoxide and the potent antioxidant bilirubin, is induced (Calabrese et al., 2003). F2-
isoprostanes are accepted biomarkers for lipid peroxidation (Basu, 2008). Induction of 
oxidative stress resulted in decreased vitamin E concentration and significantly increased 
CAT, GPx, and SOD activities in rat cortices (Tejada et al., 2007). The fact that, in the cortex 
of our rats, neither F2-isoprostane and glutathione concentrations nor the activities of the 
endogenous antioxidants SOD and Se-GPx were different between the experimental groups 
suggests that no oxidative stress had occurred in the brain. In the liver, on the other hand, the 
increases in HO-1 mRNA and protein concentrations are indicative of oxidative stress. 
Interestingly, in the liver, where differences in redox status were evident, differential 
expression of a number of genes involved in atherosclerosis, cancer, and antioxidant defence 
(see below) was observed as a result of the differences in vitamin E consumption. 
Scavenger receptor CD36, which was up-regulated in our vitamin E deficient rats, is involved 
in lipid uptake and appears to play an important role in the pathology of atherosclerosis (Azzi 
et al., 2004). CD36 binds oxidized LDL (LDLox), incorporates LDLox into macrophages and, 
thereby, leads to foam-cell formation; consequently, it is found in atherosclerotic lesions 
(Podrez et al., 2002). It has been previously shown that incubation with αT decreased CD36 
expression in human monocyte-derived macrophages (Devaraj et al., 2001) and cultured 
aortic smooth muscle cells, leading to a reduced uptake of LDLox. Down-regulation of CD36 
by αT may thus be an important mechanism for the reduction of atherosclerosis risk 
(Ricciarelli et al., 2000). 
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Steroid-5α-reductase (5α-R1), a gene which is expressed in many tissues, especially in the 
liver (Russell & Wilson, 1994), was significantly up-regulated in response to VE depletion 
(Chapter IV, Figure 2). Dihydrotestosterone, the most potent androgen, is irreversibly 
transformed from testosterone by 5α-R1 (Russell & Wilson, 1994). Androgens play an 
important role in the development of prostate cancer (Thomas et al., 2008; Tindall & 
Rittmaster, 2008) and  5α-R1 mRNA concentrations were reported to be significantly 
increased in prostate cancer compared to normal tissue (Iehle et al., 1999). Therefore, the 
inhibition of 5α-R1 might represent a potential therapeutic benefit against the development of 
prostate cancer. Conclusive evidence from human intervention trials with vitamin E is still 
lacking. Nonetheless, vitamin E supplementation resulted in a significant reduction in the 
incidence of prostate cancer in smokers (Heinonen et al., 1998). A recent meta-analysis 
supports a protective role of αT in men who are at high risk of developing prostate cancer 
(Alkhenizan & Hafez, 2007).  
The expression of mRNA for αTTP, a protein important for the retention of αT and mainly 
expressed in the liver, was down-regulated in our rats fed VE deficient diets for 6 months. In 
agreement, αTTP expression was previously shown to depend on αT intake, although the 
results reported in the literature are not consistent. While Kim et al. (1998) found significantly 
increased αTTP mRNA (but not protein) concentrations in the livers of VE depleted rats, 
Barella et al. (2004) found no differences in the mRNA concentrations of rats fed VE 
sufficient or deficient diets. Fechner and colleagues (1998) observed that both αT and δT, 
when given to VE depleted rats, increased αTTP mRNA concentrations. 
Biosynthesis of glutathione, the most important cytosolic antioxidant, requires inter alia the 
rate-limiting enzyme γ-glutamyl-cysteinyl synthetase (γGCS). This enzyme consists of two 
subunits, a heavy catalytic subunit and a light regulatory subunit (= modifier subunit). In our 
study, γGCSm (γGCS modifier subunit) gene expression was down-regulated in VE-deficient 
animals, verifying results observed by Barella and colleagues (2004), who demonstrated a 
significant up-regulation of γGCSm expression by VE supplementation. Because of its 
involvement in GSH de novo synthesis, decreased γGCS due to vitamin E deficiency could 
result in decreased GSH concentrations. 
 
With regard to the mechanisms underlying the gene-regulatory functions of vitamin E, two 
opposing positions have emerged in recent years. One group of researchers furthers the 
opinion that VE acts as an antioxidant “and nothing more” (Traber & Atkinson, 2007), while 
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the other advances the view that VE functions solely as a cellular signaling molecule and gene 
regulator, because its utilization as antioxidant would be a waste, given the large quantities of 
endogenous and exogenous antioxidants in the organism (Azzi, 2007). 
In this study, vitamin E-deficiency did neither result in significant changes in oxidative stress, 
as evidenced by similar F2-isoprostane concentrations and HO-1 mRNA concentrations, nor 
in differential gene expression in the brain. In the liver, on the other hand, where VE was 
nearly completely depleted and oxidative stress occurred (as evidenced by increased HO-1 
mRNA and protein concentrations; Chapter IV, Figure 4), differential gene expression was 
observed. This data suggests, that even small amounts of VE are sufficient to protect the brain 
against oxidative stress and, in consequence, differential gene expression. Our findings 
furthermore support the hypothesis that the gene regulatory function of VE is linked to its 
antioxidative properties. 
 
Levels of gene regulation 
The data presented within this thesis as well as published literature support the view that 
vitamin E affects gene expression on a transcriptional level. In mammals, however, mRNA 
levels often poorly correlate with the respective protein concentrations (Nelson & Keller, 
2007). Only a few years back, miRNA were discovered as molecules that effect post-
transcriptional gene-silencing by a process termed RNA interference (Rana, 2007). miRNA 
are now considered as a fundamental component in the regulatory system of gene expression 
and their biological functions are actively investigated (Girard et al., 2008). Nonetheless, it is 
important to keep in mind, that post-transcriptional gene-silencing by miRNA is not the only 
mechanism by which genes are regulated; miRNAs are more likely a means to “fine-tune” 
transcript and protein levels. 
In our study, miRNA-122a and -125b were significantly reduced in the livers of rats fed the 
vitamin E deficient compared to rats fed vitamin E sufficient diet. miRNA-122a is liver-
specific, the most abundant miRNA in the liver and is assumed to play a role in lipid 
metabolism (Esau et al., 2006). MiRNA-125b is important in inflammatory processes and 
carcinogenesis. Computational tools (Chang et al., 2004) and antisense targeting (Esau et al., 
2006; Elmen et al., 2008) are methods to propose putative miRNA targets. Target genes of 
miRNA-122a and -125b are listed in Table 1. 
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Gene expression is a multi-step process that can be subdivided into transcription, post-
transcription (splicing, degradation and protection of mRNA), translation, and post-
translational modification, which can be regulated at all steps (Moore, 2005). Transcriptional 
regulation is carried out by transcription factors (TF), which bind in the promoter-regions of 
the DNA and either enhance or repress the transcription of DNA to RNA. On the post-
transcriptional level, mRNA is affected by polyadenylation, 5’ capping (mRNA stabilization) 
and splicing (removal of introns). Alternative splicing is a mechanism by which different 
proteins can be synthesised from the same messenger RNA (Bolton et al., 1999). Also, 
mRNA silencing by e.g. miRNA, plays a role in gene regulation (see Chapter I). Post-
translational modifications of a protein determine its proper functioning and represent the 
final checkpoint in gene regulation. 
 
The mechanism(s), by which αT regulates mRNA levels of genes is (are) not completely 
understood. However, there is some evidence suggesting that αT binds to and activates the 
transcription factor tocopherol-associated protein (TAP, also known as supernatant protein 
factor). Upon binding of αT, TAP was found to translocate from the cytosol to the nucleus 
and to activate reporter gene transcription (Yamauchi et al., 2001). More recent data from 
competition binding assays, however, suggest that αT is not a specific ligand for TAP, which 
was shown to have much higher binding affinities for other molecules, including γT 
(Schneider, 2005). While specific nuclear receptors, that control gene expression, have been 
identified for vitamins A and D (retinoic acid and vitamin D receptors; reviewed by Jones et 
al. (1998)), no specific nuclear receptors have been discovered for vitamin E. However, 
tocopherols and tocotrienols were shown to activate a reporter gene coupled to the nuclear 
receptor pregnane X receptor (PXR), with γ-tocotrienol being the most potent activator of all 
studied congeners (Landes et al., 2003). Similar to TAP, PXR is known to non-specifically 
bind a wide range of xenobiotics; therefore, PXR activation by vitamin E is likely a 
mechanism to prevent accumulation of excess vitamin E (Traber & Atkinson, 2007). In the 
absence of specific vitamin E-dependent nuclear receptors and transcription factors, other 
gene-regulatory mechanisms related to he antioxidant properties of vitamin E might be 
considered to be of importance. Polyunsaturated fatty acids (Mater et al., 1999; Xu et al., 
2006) as well as oxidized lipids have been shown to alter gene expression (Koch et al., 2007). 
It might thus be possible, that αT exerts its gene-regulatory activities by protecting these fatty 
acids from oxidation. Indeed, we found increased CD36 expression in the livers of our VE-
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depleted rats concomitantly with increased oxidative stress (Chapter IV). Lipid peroxides and 
oxidative stress were previously shown to induce CD36 expression, which was prevented by 
antioxidants, including VE (Fuhrman et al., 2002). After the initial discovery that PKC 
activity is reduced by incubation with high concentrations of αT (Mahoney & Azzi, 1988), 
(half inhibitory concentration: 450 µM; a concentration that can hardly be found in the 
organism), Azzi and co-workers repeatedly claimed that this phenomenon represented a non-
antioxidative function of αT (Fazzio et al., 1997; Azzi et al., 2002; Azzi, 2007). PKC, 
however, is known to contain redox-sensitive domains that are critical for its activity 
(Gopalakrishna & Gundimeda, 2002). In agreement, hydrogen peroxide-induced oxidative 
stress increased (Abdala-Valencia & Cook-Mills, 2006), while antioxidant treatment inhibited 
PKC activity (Gopalakrishna & Gundimeda, 2002). In an in vitro study with primary 
dissociated cortical cells from 2 days-old rats, stimulation with αT induced mitogen-activated 
protein kinase and phosphatidylinositol 3-kinase pathways, which are important for neuronal 
survival (Numakawa et al., 2006), demonstrating that further kinase pathways are influenced 
by αT. Thus, it seems unlikely that αT-mediated changes in PKC activity are the result of a 
specific cellular signalling function, but more likely due to an antioxidant phenomenon 
(Traber & Atkinson, 2007). 
 
CONCLUSION 
In conclusion, the data from the present thesis suggest tissue-specific differences in the 
accumulation and retention of vitamin E in the rat and, consequently, in the susceptibility of 
different organs to oxidative stress. Furthermore, our data indicate that oxidative stress may 
be partly responsible for the observed vitamin E-dependent gene regulation. In addition, the 
regulation of hepatic miRNA concentrations may represent a novel biological function of 
vitamin E. 
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Table 1: Life weight gain of rats fed diets with <1, 9, 18, and 146 mg TE/kg diet for 24 weeks. 
 
 Week Randomization 1 2 3 4 5 6 
        
Animal 
Treatment     
(mg TE/kg diet)  Body weight (g)  
1 18 59.6 82.1 117.4 149.3 183.6 212.3 238.5 
2 18 54.7 74.0 107.9 138.2 175.1 195.2 221.8 
3 18 54.2 79.5 113.8 148.6 186.3 211.6 233.8 
4 18 51.9 74.2 108.6 142.8 184.8 207.7 234.0 
5 18 51.6 70.5 102.2 132.5 174.7 196.7 221.7 
6 18 46.8 66.9 103.6 132.5 186.3 203.4 233.4 
7 18 45.2 65.9 104.2 137.2 190.2 215.4 241.3 
8 18 42.6 63.9 100.5 133.8 182.1 206.0 233.8 
9 9 59.1 81.4 112.3 145.9 182.6 201.7 229.3 
10 9 54.8 76.8 107.3 140.9 181.3 204.6 224.7 
11 9 53.2 75.9 113.4 143.9 182.8 204.4 226.6 
12 9 51.9 73.8 113.2 145.3 185.4 210.6 235.5 
13 9 51.6 73.7 113.2 139.9 183.8 216.0 239.8 
14 9 47.4 69.5 104.8 131.3 171.8 194.9 219.2 
15 9 44.9 66.5 102.9 132.7 176.1 202.2 225.6 
16 9 41.8 63.2 101.6 135.2 182.6 210.7 234.5 
17 <1 59.0 80.9 115.6 150.8 187.4 212.4 233.7 
18 <1 57.1 79.2 113.2 149.8 188.4 208.7 229.9 
19 <1 52.9 77.0 115.0 152.8 194.7 219.0 242.1 
20 <1 52.0 74.9 112.1 149.9 191.4 216.1 244.9 
21 <1 50.1 71.2 107.5 137.2 179.3 206.7 229.8 
22 <1 48.0 69.0 108.1 141.0 190.1 218.2 240.5 
23 <1 44.6 62.5 98.4 130.6 174.8 201.7 227.7 
24 <1 43.0 64.0 103.1 137.5 178.9 211.6 240.7 
25 146 58.6 79.7 112.2 142.8 186.1 206.0 232.8 
26 146 58.6 79.3 117.4 154.3 194.1 216.1 236.8 
27 146 52.6 73.0 108.7 139.3 182.4 206.2 232.5 
28 146 52.4 74.4 109.1 141.0 177.2 200.9 222.8 
29 146 49.6 69.6 104.0 132.7 167.9 191.8 212.6 
30 146 49.1 70.5 105.7 133.5 173.9 195.8 215.9 
31 146 44.5 64.0 99.1 128.4 167.7 191.7 215.7 
32 146 43.8 63.4 100.7 129.8 173.4 201.9 227.4 
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Table 1 (continued) 
 
Animal Week Randomization 7 8 9 10 11 12 
        
 
Treatment     
(mg TE/kg diet)   Body weight (g)  
1 18 59.6 258.0 278.4 292.4 305.5 318.6 330.3 
2 18 54.7 241.6 260.2 271.5 283.9 294.5 306.1 
3 18 54.2 247.6 266.3 279.8 291.4 304.4 314.0 
4 18 51.9 252.2 272.8 282.5 294.7 308.8 318.6 
5 18 51.6 242.6 258.9 270.2 283.0 292.4 299.6 
6 18 46.8 256.5 278.9 291.4 304.5 313.8 326.2 
7 18 45.2 264.9 286.4 300.9 316.4 322.5 342.0 
8 18 42.6 255.8 278.8 297.7 308.5 314.9 337.1 
9 9 59.1 246.9 262.7 276.1 285.6 297.9 302.4 
10 9 54.8 242.8 260.7 274.1 284.9 297.6 305.6 
11 9 53.2 241.7 259.2 269.8 282.7 295.2 301.9 
12 9 51.9 253.8 272.3 287.1 300.4 313.2 320.7 
13 9 51.6 263.3 282.6 296.4 302.1 312.4 324.0 
14 9 47.4 241.8 258.8 274.0 281.9 290.3 297.6 
15 9 44.9 245.4 261.4 275.4 285.5 287.4 304.3 
16 9 41.8 258.6 280.1 295.3 310.9 319.8 334.9 
17 <1 59.0 251.2 269.1 285.2 296.5 308.0 314.8 
18 <1 57.1 249.0 266.9 279.0 289.0 303.1 312.0 
19 <1 52.9 264.1 287.5 299.7 309.6 318.7 332.1 
20 <1 52.0 268.8 287.7 300.3 312.9 318.8 335.3 
21 <1 50.1 250.9 271.2 284.9 294.2 304.9 313.7 
22 <1 48.0 263.8 284.4 298.7 310.2 323.6 332.1 
23 <1 44.6 251.8 270.6 287.4 300.1 312.6 329.9 
24 <1 43.0 263.6 284.6 299.9 314.5 329.9 342.5 
25 146 58.6 249.9 270.0 284.2 294.7 301.5 317.7 
26 146 58.6 258.6 278.0 295.3 301.7 315.9 327.1 
27 146 52.6 252.8 256.3 285.8 300.0 304.9 311.6 
28 146 52.4 241.3 271.4 268.6 277.0 286.4 293.6 
29 146 49.6 229.3 246.5 255.1 262.9 274.1 279.2 
30 146 49.1 233.5 251.6 262.2 272.1 285.0 291.5 
31 146 44.5 245.2 262.6 271.6 283.9 292.2 300.7 
32 146 43.8 234.5 255.3 264.9 280.0 286.8 297.1 
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Table 1 (continued) 
 
Animal Week 13 14 15 16 17 18 
       
 
Treatment     
(mg TE/kg diet)  Body weight (g)  
1 18 355.5 342.0 349.6 358.5 365.5 369.0 
2 18 312.5 314.1 316.8 322.5 328.0 330.2 
3 18 318.6 323.1 329.8 335.9 341.8 347.7 
4 18 324.6 329.6 331.7 338.7 346.0 350.7 
5 18 304.9 306.4 308.1 311.7 319.5 322.0 
6 18 332.1 335.1 333.9 338.0 344.4 345.7 
7 18 349.4 351.6 355.6 359.6 373.5 378.1 
8 18 347.5 349.8 357.3 361.4 370.2 372.4 
9 9 309.5 312.3 314.3 323.0 332.4 333.5 
10 9 313.2 315.2 316.7 326.2 332.0 332.7 
11 9 308.8 309.7 313.8 316.4 326.0 325.6 
12 9 329.5 330.2 338.2 343.2 357.1 354.1 
13 9 338.4 344.5 351.3 356.6 362.7 366.7 
14 9 309.4 314.4 319.5 324.4 333.2 338.4 
15 9 313.6 315.6 322.0 331.0 334.5 339.0 
16 9 347.3 347.7 353.0 364.9 368.0 372.1 
17 <1 323.7 321.6 328.6 334.2 334.8 340.7 
18 <1 320.8 322.4 329.4 340.0 345.5 350.5 
19 <1 341.3 346.5 353.4 359.8 365.0 368.6 
20 <1 345.0 344.5 348.7 357.0 363.8 368.7 
21 <1 322.3 325.4 331.9 338.5 344.4 343.6 
22 <1 344.2 345.5 351.3 357.5 364.3 363.8 
23 <1 337.6 336.0 343.7 345.7 352.3 356.6 
24 <1 355.4 359.3 367.0 373.0 378.2 377.3 
25 146 324.9 323.7 327.7 339.5 346.6 354.0 
26 146 337.0 336.2 343.1 351.2 357.5 364.0 
27 146 322.7 321.3 325.1 330.2 334.3 338.6 
28 146 301.8 306.3 312.7 319.1 322.6 326.3 
29 146 285.6 286.5 288.4 299.4 302.1 302.8 
30 146 296.3 296.7 299.7 307.9 314.7 316.0 
31 146 309.9 314.1 320.6 330.0 330.8 336.2 
32 146 303.7 306.1 312.6 321.9 329.0 332.1 
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Table 1 (continued) 
 
Animal Week 19 20 21 22 23 24 Final 
        
 
Treatment     
(mg TE/kg diet)   Body weight (g)   
1 18 372.7 374.8 382.5 389.4 390.3 392.6 386.9 
2 18 330.6 335.6 343.8 346.3 348.7 350.5 346.7 
3 18 352.1 356.2 360.7 361.7 365.8 371.2 364.7 
4 18 353.0 360.5 362.4 365.3 369.5 372.3 367.1 
5 18 329.7 333.9 339.3 345.2 348.3 352.2 346.2 
6 18 355.5 361.4 362.5 364.7 370.7 376.5 367.7 
7 18 386.6 391.6 397.0 399.4 402.3 413.9 404.7 
8 18 377.3 381.9 384.6 389.9 394.3 401.6 393.0 
9 9 336.7 343.3 347.1 353.2 355.0 356.5 350.8 
10 9 340.1 345.9 348.2 350.8 352.2 358.8 353.3 
11 9 329.0 336.2 337.8 342.0 348.0 351.2 349.5 
12 9 362.2 371.5 372.3 378.4 386.2 388.8 384.5 
13 9 369.6 377.1 381.8 385.0 389.7 394.6 387.5 
14 9 339.2 343.1 349.3 354.0 353.5 361.3 354.5 
15 9 342.9 345.8 355.4 356.8 364.2 367.3 360.0 
16 9 374.3 378.9 384.1 386.0 393.7 396.4 392.6 
17 <1 340.4 345.7 347.3 349.8 348.8 349.3 342.2 
18 <1 351.4 351.2 350.1 356.9 361.7 367.8 354.5 
19 <1 366.9 365.3 366.0 373.4 375.3 378.9 375.7 
20 <1 364.0 359.0 362.2 371.5 374.6 378.6 374.4 
21 <1 343.6 349.2 350.5 353.7 359.1 362.8 358.2 
22 <1 365.4 368.4 369.1 370.0 374.9 375.9 373.3 
23 <1 366.3 369.7 369.2 368.5 369.4 371.9 362.6 
24 <1 383.3 384.2 382.4 381.9 361.4 366.5 361.4 
25 146 354.2 358.5 366.5 370.6 372.8 377.8 373.9 
26 146 362.6 365.4 370.9 378.9 376.5 384.4 378.0 
27 146 347.2 350.4 357.0 357.9 364.4 364.2 357.8 
28 146 328.6 334.7 339.8 344.7 350.3 354.4 348.3 
29 146 304.9 308.7 309.5 311.8 314.4 315.7 313.9 
30 146 320.3 324.9 324.7 332.9 332.2 338.2 330.9 
31 146 337.7 341.4 346.4 348.5 350.3 354.8 347.7 
32 146 336.0 338.9 345.4 351.9 350.3 356.3 348.3 
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Table 2: Concentrations of α- and γ-tocopherol in the plasma of rats fed diets with <1, 9, 18, and 146 
mg TE/kg diet, respectively, for 24 weeks. 
 
Animal Treatment αT Plasma γT Plasma 
 mg TE/kg diet (nmol/mL) (nmol/ml) 
1 18 16.6 0.472 
2 18 19.9 0.654 
3 18 17.2 0.509 
4 18 17.6 0.616 
5 18 19.3 0.557 
6 18 16.9 0.552 
7 18 17.0 0.589 
8 18 17.0 0.481 
9 9 11.5 0.532 
10 9 10.6 0.509 
11 9 12.2 0.882 
12 9 11.3 0.670 
13 9 11.7 0.517 
14 9 11.9 0.585 
15 9 8.7 0.444 
16 9 8.7 0.423 
17 <1 0.34 0.004 
18 <1 0.34 0.009 
19 <1 0.35 0.008 
20 <1 0.32 0.010 
21 <1 0.36 0.009 
22 <1 0.38 0.010 
23 <1 0.37 0.010 
24 <1 0.28 0.006 
25 146 41.8 0.059 
26 146 41.0 0.061 
27 146 33.1 0.047 
28 146 37.4 0.073 
29 146 42.2 0.077 
30 146 34.1 0.043 
31 146 35.5 0.082 
32 146 39.8 0.097 
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Table 2 (continued) 
 
Animal Treatment Cholesterol αT/Cholesterol γT/Cholesterol 
 mg TE/kg diet (mmol/L) (mmol/mol) (mmol/mol) 
1 18 2.52 6.59 0.187 
2 18 2.73 7.27 0.239 
3 18 2.36 7.27 0.215 
4 18 2.70 6.53 0.229 
5 18 2.57 7.53 0.217 
6 18 2.20 7.65 0.251 
7 18 2.49 6.81 0.236 
8 18 2.53 6.73 0.190 
9 9 2.69 4.27 0.198 
10 9 2.44 4.34 0.208 
11 9 2.91 4.20 0.303 
12 9 2.75 4.11 0.244 
13 9 2.58 4.52 0.200 
14 9 2.84 4.17 0.206 
15 9 2.30 3.79 0.193 
16 9 2.27 3.81 0.186 
17 <1 2.17 0.16 0.002 
18 <1 2.18 0.16 0.004 
19 <1 2.37 0.15 0.003 
20 <1 2.12 0.15 0.005 
21 <1 2.37 0.15 0.004 
22 <1 2.33 0.16 0.004 
23 <1 2.49 0.15 0.004 
24 <1 1.79 0.16 0.004 
25 46 3.09 13.5 0.019 
26 146 2.86 14.4 0.021 
27 146 2.50 13.3 0.019 
28 146 2.70 13.8 0.031 
29 146 3.00 14.1 0.026 
30 146 2.60 13.1 0.017 
31 146 2.56 13.9 0.032 
32 146 3.07 12.9 0.031 
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Table 3: Concentrations of α- and γ-tocopherol in cortex and hippocampus of rats fed diets with <1, 9, 
18, and 146 mg TE/kg diet, respectively, for 24 weeks. 
 
Animal Treatment αT Cortex γT Cortex αT Hippocampus 
 (mg TE/kg diet) (nmol/g) (nmol/g) (nmol/g) 
1 18 25.51 0.189 9.96 
2 18 21.22 0.142 5.11 
3 18 17.28 0.128 5.38 
4 18 15.07 0.111 12.87 
5 18 23.13 0.166 9.64 
6 18 19.77 0.157 10.19 
7 18 23.81 0.186 n.d. 
8 18 23.65 0.183 14.31 
9 9 22.23 0.151 6.91 
10 9 17.32 0.119 3.36 
11 9 14.68 0.121 10.35 
12 9 12.99 0.106 7.16 
13 9 15.56 0.145 n.d. 
14 9 16.49 0.135 n.d. 
15 9 18.19 0.157 14.32 
16 9 16.24 0.132 5.09 
17 <1 5.75 n.d. 2.32 
18 <1 2.85 0.008 n.d. 
19 <1 2.00 0.006 n.d. 
20 <1 3.04 0.011 2.74 
21 <1 3.12 0.009 n.d. 
22 <1 4.17 0.008 1.43 
23 <1 4.81 n.d. 2.73 
24 <1 4.48 0.008 0.77 
25 146 38.53 0.076 19.36 
26 146 27.26 0.031 8.65 
27 146 23.61 0.043 n.d. 
28 146 29.35 0.050 n.d. 
29 146 27.54 0.056 16.37 
30 146 29.78 0.049 17.51 
31 146 30.34 0.058 14.74 
32 146 33.84 0.062 16.82 
n.d. = not detectable 
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Table 4: Concentrations of α- and γ-tocopherol in liver, lung, and muscle of rats fed diets with <1, 9, 
18, and 146 mg TE/kg diet, respectively, for 24 weeks. 
 
Animal Treatment αT Liver γT Liver αT Lung γT Lung αT Muscle γT Muscle 
 mg TE/kg diet nmol/g nmol/g nmol/g nmol/g nmol/g nmol/g 
1 18 27.5 0.397 20.0 0.570 11.9 0.584 
2 18 32.3 0.441 19.6 0.645 13.1 0.311 
3 18 26.1 0.359 21.3 0.606 10.4 0.272 
4 18 28.2 0.405 17.7 0.609 11.2 0.384 
5 18 26.2 0.442 17.0 0.582 9.2 0.391 
6 18 29.2 0.443 27.2 0.759 11.1 0.312 
7 18 29.9 0.446 25.3 0.807 15.3 0.339 
8 18 28.8 0.357 21.2 0.591 11.5 0.308 
9 9 14.2 0.289 11.9 0.443 5.7 0.196 
10 9 18.3 0.377 13.0 0.544 7.9 0.197 
11 9 12.1 0.357 13.1 0.675 7.3 0.163 
12 9 13.6 0.347 12.2 0.544 6.8 0.218 
13 9 15.9 0.313 12.5 0.571 8.1 0.229 
14 9 14.9 0.345 10.0 0.520 7.8 0.252 
15 9 16.8 0.371 11.2 0.466 7.4 0.215 
16 9 14.8 0.329 13.2 0.546 8.0 0.221 
17 <1 0.39 0.014 0.45 0.015 0.48 0.038 
18 <1 0.38 0.016 0.55 0.054 0.42 0.045 
19 <1 0.28 0.014 0.35 0.084 0.30 0.038 
20 <1 0.31 0.018 0.55 0.141 0.27 0.031 
21 <1 0.29 0.007 0.30 0.017 0.52 0.033 
22 <1 0.31 0.010 0.40 0.025 0.48 0.017 
23 <1 0.30 0.016 0.28 0.011 0.25 0.021 
24 <1 0.37 0.014 0.31 0.011 0.36 0.009 
25 146 98.8 0.092 47.7 0.044 24.9 0.081 
26 146 126.7 0.106 46.9 0.048 22.2 0.078 
27 146 72.7 0.095 41.0 0.041 17.8 0.059 
28 146 111.2 0.099 42.3 0.047 19.6 0.059 
29 146 108.3 0.106 43.4 0.174 20.3 0.052 
30 146 103.1 0.109 44.8 0.193 16.7 0.060 
31 146 116.7 0.106 37.1 0.085 18.3 0.040 
32 146 96.5 0.118 41.5 0.077 19.9 0.054 
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Table 5: Relative expression of selective genes in the cortex of rats fed diets with <1, 9, 18, and 146 
mg TE/kg diet, respectively, for 24 weeks. Values are the ratio of target-gene/β-actin. 
 
Animal Treatment Gene 
 (mg TE/kg diet) APP Apba1 Adam-10 Bace-1 Bax Bcl-2 
1 18 2.23 1.20 1.24 1.26 1.39 1.08 
2 18 0.88 1.07 1.30 1.43 0.93 0.94 
3 18 0.97 0.98 1.08 1.08 0.96 0.93 
4 18 1.04 0.93 1.01 1.17 1.02 1.05 
5 18 1.05 1.89 1.06 0.91 1.36 1.52 
6 18 1.16 1.51 0.80 0.68 0.85 1.18 
7 18 1.71 1.92 0.97 0.92 1.14 1.31 
8 18 1.07 1.33 1.00 1.02 0.99 1.23 
9 9 1.08 0.62 0.71 0.67 0.75 1.05 
10 9 0.90 0.78 0.95 0.91 0.78 1.00 
11 9 1.36 1.35 1.39 1.29 0.99 1.30 
12 9 0.91 1.24 1.07 1.16 1.22 1.08 
13 9 1.01 1.04 0.82 0.70 0.77 0.90 
14 9 1.03 1.06 0.64 0.68 0.66 0.87 
15 9 1.29 1.28 0.81 0.70 0.89 1.09 
16 9 1.47 1.65 0.87 0.96 1.08 1.05 
17 <1 2.17 0.83 1.10 1.09 0.86 1.20 
18 <1 0.98 0.87 1.08 1.22 0.92 1.23 
19 <1 1.40 0.90 1.32 1.25 1.14 1.04 
20 <1 1.09 0.80 0.77 0.87 1.12 1.06 
21 <1 1.23 1.24 0.98 0.90 0.90 1.13 
22 <1 1.13 1.71 0.90 0.87 0.95 1.25 
23 <1 1.21 0.85 0.68 0.63 0.83 0.82 
24 <1 1.45 1.28 0.72 0.86 0.81 0.94 
25 146 1.10 1.13 0.74 0.71 0.81 1.02 
26 146 1.27 1.67 1.08 0.96 1.07 1.15 
27 146 1.13 1.17 0.82 0.78 0.97 1.28 
28 146 1.19 1.22 0.75 0.83 0.88 0.92 
29 146 1.47 1.05 1.03 1.16 0.93 1.36 
30 146 1.12 1.01 1.05 1.10 1.01 1.04 
31 146 1.18 1.22 1.41 1.40 1.09 1.12 
32 146 1.22 0.78 0.88 0.89 0.92 1.20 
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Table 5 (continued) 
 
Animal Treatment Gene 
 (mg TE/kg diet) ECE IDE Neprilysin αTTP HO-1 AChE 
1 18 1.47 1.28 0.89 1.04 1.42 0.93 
2 18 1.03 0.88 1.05 1.13 1.65 0.99 
3 18 0.99 1.05 1.01 0.86 0.86 0.98 
4 18 0.92 1.08 0.99 0.97 1.46 0.93 
5 18 1.42 1.31 2.31 1.87 0.94 1.28 
6 18 0.79 0.89 1.59 1.21 1.67 1.11 
7 18 1.27 1.11 1.18 1.16 1.90 1.26 
8 18 0.90 1.00 1.00 1.11 1.66 1.39 
9 9 0.95 0.85 0.77 0.73 1.17 0.61 
10 9 0.83 0.65 0.53 0.80 1.25 1.21 
11 9 0.98 1.14 1.23 1.28 1.74 0.80 
12 9 0.75 0.98 0.66 1.15 1.30 0.89 
13 9 0.69 0.67 0.87 0.89 0.98 1.09 
14 9 0.70 0.62 3.21 1.03 1.60 1.34 
15 9 1.11 0.87 1.04 1.19 1.77 1.28 
16 9 0.97 1.14 1.13 1.53 1.32 1.13 
17 <1 1.30 0.90 0.60 0.96 1.35 0.92 
18 <1 0.91 0.91 1.68 0.97 1.20 1.17 
19 <1 1.26 1.12 0.65 1.38 1.73 0.72 
20 <1 0.90 0.93 2.69 1.23 1.40 1.97 
21 <1 1.01 0.98 1.02 0.91 0.88 1.03 
22 <1 0.91 0.87 1.28 1.01 1.56 1.18 
23 <1 0.82 0.71 2.40 0.97 1.34 1.14 
24 <1 1.13 0.97 2.32 1.07 1.34 2.69 
25 146 0.89 0.73 1.39 1.04 1.91 1.05 
26 146 0.86 1.20 1.02 1.50 1.54 1.34 
27 146 0.93 0.90 1.14 0.98 1.24 1.62 
28 146 0.95 0.77 0.99 1.17 1.30 1.33 
29 146 1.01 1.03 1.29 1.00 1.01 1.70 
30 146 0.87 1.01 1.14 0.95 1.23 0.98 
31 146 1.24 1.33 1.17 1.13 1.28 1.02 
32 146 0.94 0.81 0.80 1.04 0.97 1.08 
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Table 6: Relative expression of selective genes in the hippocampus of rats fed diets with <1, 9, 18, 
and 146 mg TE/kg diet, respectively, for 24 weeks. Values are the ratio of target-gene/β-actin. 
 
Animal Treatment Gene 
 (mg TE/kg diet) APP Apba1 Adam-10 Bace-1 Bax Bcl-2 
1 18 0.89 0.55 0.93 0.76 0.88 1.01 
2 18 1.52 0.73 1.18 0.91 0.84 1.30 
3 18 0.91 0.95 0.98 0.90 0.92 1.38 
4 18 0.80 1.17 1.00 0.71 0.78 1.15 
5 18 0.85 1.13 0.81 0.74 0.95 1.15 
6 18 1.00 0.90 0.99 0.73 0.94 1.00 
7 18 1.09 1.01 1.17 0.59 0.95 1.13 
8 18 0.99 1.11 0.92 0.78 0.96 1.09 
9 9 1.02 0.86 0.96 0.68 0.77 1.04 
10 9 0.83 1.11 0.88 0.83 0.79 0.95 
11 9 0.69 0.71 0.71 0.76 0.73 1.05 
12 9 0.98 1.22 0.95 0.94 0.92 1.25 
13 9 0.92 0.81 0.81 0.78 0.88 0.88 
14 9 0.80 0.99 0.76 0.71 0.82 0.89 
15 9 0.86 0.73 0.76 0.82 0.89 0.99 
16 9 0.93 0.91 0.84 0.76 0.94 1.03 
17 <1 0.75 0.83 0.90 0.81 0.93 1.29 
18 <1 0.55 0.84 0.78 0.66 0.72 0.88 
19 <1 0.81 0.91 0.73 0.74 0.99 0.93 
20 <1 0.83 0.83 0.91 0.65 0.87 1.17 
21 <1 1.32 1.30 1.26 1.15 1.48 1.60 
22 <1 0.88 0.88 0.84 0.64 1.00 1.12 
23 <1 1.13 1.03 0.96 0.90 1.20 1.26 
24 <1 0.84 0.93 0.84 0.73 0.94 0.97 
25 146 0.84 1.23 0.95 0.76 1.12 1.07 
26 146 1.07 1.20 1.00 0.63 0.82 1.11 
27 146 1.12 0.96 0.94 0.77 1.03 1.19 
28 146 0.74 0.88 0.66 0.74 0.80 0.92 
29 146 0.94 0.90 0.85 0.77 0.84 1.37 
30 146 1.32 0.89 0.79 0.69 0.76 0.92 
31 146 0.82 0.79 0.75 0.69 0.90 1.03 
32 146 0.76 0.78 0.65 0.81 0.89 1.02 
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Table 6 (continued) 
 
Animal Treatment Gene 
 (mg TE/kg diet) ECE IDE Neprilysin αTTP HO-1 AChE 
1 18 0.78 0.86 0.71 0.87 0.72 1.07 
2 18 0.94 0.72 0.93 0.69 0.82 0.85 
3 18 0.86 0.90 0.84 0.85 1.05 1.10 
4 18 0.93 0.77 1.08 0.99 0.74 1.25 
5 18 0.98 0.88 0.96 1.13 0.84 0.94 
6 18 0.93 1.18 0.85 0.99 0.79 0.96 
7 18 1.09 1.36 1.12 1.58 0.57 1.32 
8 18 1.09 1.24 1.06 0.97 0.91 0.94 
9 9 0.80 0.62 0.77 0.94 0.77 1.18 
10 9 0.82 0.66 1.19 1.05 0.68 1.26 
11 9 0.81 0.84 0.89 0.88 0.76 1.09 
12 9 1.14 0.74 1.24 1.13 0.98 1.49 
13 9 0.96 1.01 0.89 0.80 0.75 0.78 
14 9 0.80 1.04 0.95 0.83 0.45 0.68 
15 9 0.95 1.01 0.92 0.80 0.48 0.89 
16 9 0.96 1.09 0.97 0.86 0.57 0.84 
17 <1 0.90 0.73 0.76 0.97 0.74 1.08 
18 <1 0.72 0.50 0.77 0.72 0.68 0.91 
19 <1 0.88 0.58 0.80 1.07 0.61 0.96 
20 <1 0.81 0.82 0.91 1.00 0.65 0.97 
21 <1 1.24 1.51 1.32 1.36 1.15 1.29 
22 <1 0.90 1.00 0.78 0.79 1.20 0.83 
23 <1 1.21 1.33 1.07 1.06 1.17 0.89 
24 <1 0.95 0.98 0.67 0.95 0.62 0.77 
25 146 1.18 1.12 0.69 1.04 0.56 0.66 
26 146 0.96 1.03 0.93 1.19 0.79 0.80 
27 146 1.05 1.14 1.09 1.21 0.64 1.02 
28 146 0.76 0.87 0.74 0.82 0.56 0.73 
29 146 0.80 0.71 0.90 1.05 0.70 1.12 
30 146 0.77 0.58 0.96 0.85 0.48 0.94 
31 146 0.82 0.04 0.88 1.05 0.59 1.25 
32 146 0.80 0.56 0.97 0.99 0.73 0.97 
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Table 7: Antioxidant enzyme activities and glutathione concentrations in the cortex of rats fed diets 
with <1, 9, 18, and 146 mg TE/kg diet, respectively, for 24 weeks. 
 
Animal Treatment Protein concentration SOD activity Se-GPx activity GSH concentration 
 (mg TE/kg diet) (mg/mL) (U/mg protein) (mU/mg protein) (nmol/mg protein) 
1 18 58.8 12.2 80.6 21.2 
2 18 65.0 12.5 86.1 23.0 
3 18 61.7 12.7 79.9 22.2 
4 18 48.5 15.5 85.9 24.8 
5 18 48.3 15.8 114.6 27.6 
6 18 66.6 12.3 80.5 23.1 
7 18 56.6 13.9 94.6 23.1 
8 18 54.7 13.0 101.1 26.3 
9 9 48.3 14.6 95.8 26.1 
10 9 46.9 9.9 104.7 27.8 
11 9 47.7 16.7 106.4 28.0 
12 9 53.5 14.6 117.6 22.6 
13 9 47.9 13.5 98.7 26.1 
14 9 61.8 11.3 72.1 23.1 
15 9 61.1 11.4 80.8 23.7 
16 9 56.8 12.0 88.3 23.3 
17 <1 55.3 11.5 94.9 23.1 
18 <1 45.5 16.4 98.1 29.9 
19 <1 62.1 14.0 76.5 23.8 
20 <1 61.1 13.1 91.5 21.1 
21 <1 65.4 11.6 67.3 20.6 
22 <1 43.2 15.7 105.6 29.9 
23 <1 65.4 11.5 75.6 22.2 
24 <1 44.3 16.4 94.4 28.8 
25 146 50.2 15.1 125.5 24.8 
26 146 50.6 12.9 79.0 24.6 
27 146 50.4 15.4 100.2 27.2 
28 146 47.0 11.9 91.4 25.5 
29 146 57.4 15.1 87.2 24.9 
30 146 56.9 12.2 72.7 25.2 
31 146 44.6 15.1 117.4 27.9 
32 146 43.8 15.6 110.4 27.8 
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Table 8: F2-isoprostane concentrations in the cortex of rats fed diets with <1, 9, 18, and 146 mg TE/kg 
diet, respectively, for 24 weeks. 
 
Animal Treatment F2-isoprostane concentration 
 (mg TE/kg diet) (pg/mg net weight) (ng/mg protein) 
1 18 26.2 0.399 
2 18 20.2 0.304 
3 18 19.5 0.286 
4 18 21.8 0.292 
5 18 27.2 0.358 
6 18 27.6 0.430 
7 18 30.3 0.427 
8 18 25.2 0.379 
9 9 27.4 0.388 
10 9 16.9 0.251 
11 9 23.4 0.329 
12 9 23.4 0.305 
13 9 31.1 0.387 
14 9 25.5 0.420 
15 9 36.7 0.507 
16 9 23.3 0.357 
17 <1 33.7 0.494 
18 <1 27.4 0.384 
19 <1 23.9 0.317 
20 <1 23.8 0.338 
21 <1 39.8 0.561 
22 <1 42.3 0.561 
23 <1 30.3 0.403 
24 <1 25.7 0.398 
25 146 26.5 0.389 
26 146 30.0 0.401 
27 146 19.6 0.295 
28 146 20.9 0.273 
29 146 27.5 0.361 
30 146 29.6 0.407 
31 146 24.8 0.350 
32 146 25.5 0.428 
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Table 9: Relative protein concentration of Bcl-2. Bax and β-actin in cortex homogenates of rats fed 
diets with <1, 9, 18, and 146 mg TE/kg diet, respectively, for 24 weeks. Values are the ratio of target 
protein/β-actin. 
 
Animal Treatment Bcl-2 Bax 
 (mg TE/kg diet)   
1 18 0.211 0.188 
2 18 0.127 0.192 
3 18 0.359 0.573 
4 18 0.477 0.594 
5 18 1.126 1.805 
6 18 1.135 2.703 
9 9 0.157 0.186 
10 9 0.178 0.215 
11 9 0.616 0.573 
12 9 0.489 0.627 
13 9 1.151 2.011 
14 9 1.689 1.553 
17 <1 0.162 0.237 
18 <1 0.118 0.198 
19 <1 0.659 0.513 
20 <1 0.409 0.525 
21 <1 0.830 1.910 
22 <1 0.879 2.016 
25 146 0.364 0.283 
26 146 0.200 0.276 
27 146 0.442 0.526 
28 146 0.852 0.774 
29 146 1.271 2.430 
30 146 0.935 1.625 
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Table 10: Relative expression of selective genes in the liver of rats fed diets with <1, 9, 18, and 
146 mg TE/kg diet, respectively, for 24 weeks. Values are the ratio of target gene/β-actin. 
 
Animal Treatment 5α-R1 CD36 γGCSm αTTP 
 (mg TE/kg diet)     
1 18 1.01 1.39 0.86 1.25 
2 18 0.97 1.30 0.97 1.64 
3 18 0.68 0.88 1.36 1.01 
4 18 0.86 0.98 1.25 1.33 
5 18 0.88 1.42 1.66 1.26 
6 18 0.98 2.55 2.03 2.02 
7 18 1.32 1.86 1.76 1.27 
8 18 1.26 1.20 1.07 1.37 
9 9 1.38 1.68 1.18 1.29 
10 9 1.07 1.06 1.45 1.42 
11 9 1.20 1.87 1.17 1.53 
12 9 0.96 1.57 1.10 1.88 
13 9 1.30 1.19 1.21 1.57 
14 9 0.98 1.44 1.64 1.91 
15 9 1.60 1.32 1.80 1.47 
16 9 0.81 0.93 1.51 1.23 
17 <1 1.82 3.08 0.70 0.79 
18 <1 2.12 3.23 0.47 0.93 
19 <1 1.36 2.67 0.84 1.22 
20 <1 1.19 3.05 0.88 1.19 
21 <1 1.56 3.53 0.71 1.15 
22 <1 1.25 2.65 0.74 1.15 
23 <1 1.56 2.76 0.92 1.25 
24 <1 1.30 2.23 0.80 1.25 
25 146 0.94 1.15 1.52 1.32 
26 146 1.16 1.14 1.24 1.57 
27 146 0.75 1.49 1.32 1.54 
28 146 0.68 1.27 1.19 1.54 
29 146 1.00 1.74 1.10 1.96 
30 146 0.80 1.59 1.61 2.04 
31 146 0.66 1.39 1.37 1.35 
32 146 1.28 1.27 0.96 1.59 
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Table 11: Relative expression of miRNA concentrations in the liver of rats fed diets with <1, 9, 18, 
and 146 mg TE/kg diet, respectively, for 24 weeks. Values are ratio of target miRNA/snoRNA. 
 
Animal Treatment miR-122a miR-125b 
 (mg TE/kg diet)   
1 18 1.38 1.12 
2 18 1.18 1.22 
3 18 1.31 1.20 
4 18 1.46 1.21 
5 18 1.09 1.29 
6 18 1.50 1.26 
7 18 1.16 1.56 
8 18 1.31 1.43 
9 9 1.10 1.08 
10 9 1.07 1.00 
11 9 1.09 1.36 
12 9 0.97 1.06 
13 9 1.19 1.40 
14 9 1.18 1.19 
15 9 1.21 1.29 
16 9 0.97 1.21 
17 <1 0.98 1.12 
18 <1 0.96 0.78 
19 <1 0.87 1.04 
20 <1 1.05 1.11 
21 <1 1.28 1.06 
22 <1 1.16 1.12 
23 <1 1.30 0.98 
24 <1 1.47 1.07 
25 146 1.10 1.16 
26 146 1.11 0.92 
27 146 0.93 1.26 
28 146 1.09 1.18 
29 146 1.20 0.89 
30 146 0.98 0.99 
31 146 1.11 1.23 
32 146 1.14 1.30 
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Table 12: Relative protein concentrations of HO-1 in liver homogenates of rats fed diets with <1, 9, 
18, and 146 mg TE/kg diet, respectively, for 24 weeks. Values are the ratio of HO-1/β-actin. 
 
Animal Treatment HO-1 
 (mg TE/kg diet)  
1 18 0.356 
2 18 0.696 
3 18 0.569 
4 18 0.098 
5 18 0.261 
7 18 0.629 
8 18 0.528 
9 9 0.463 
10 9 0.575 
11 9 0.402 
12 9 0.487 
14 9 0.630 
15 9 0.888 
16 9 0.924 
17 <1 0.560 
18 <1 0.494 
19 <1 0.376 
20 <1 0.444 
21 <1 0.448 
22 <1 0.615 
23 <1 0.746 
24 <1 0.943 
25 146 0.400 
26 146 0.470 
27 146 0.400 
28 146 0.304 
29 146 0.505 
30 146 0.227 
31 146 0.616 
32 146 0.620 
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